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Preface 
Doxorubicin, is one of the most effective cytostatic drugs in clinical 
practice. Its use, however, is accompanied with considerable toxicity. The 
toxic effects in the short term are bone marrow depression, nausea and 
vomiting, alopecia and mucositis. In the long term, treatment with 
doxorubicin potentially results in cardiomyopathy and clinically overt 
heart failure. 
The interest of the clinician in decreasing the toxicity of this very 
important drug in cancer medicine, the interest of the Laboratory for 
Pathology and the Laboratory for Pharmacology of the Dutch National 
Institute of Public Health and Environmental Hygiene in developing the IgM 
inimunocytoma bearing Lou/M Wsl rat as a model for studying the cytostatic 
action and toxicity of antitumor drugs, and the interest of the 
Pharmaceutical Department of the State University of Utrecht in developing 
the technology of liposomes as drug carriers have been the starting point 
for the investigations described in this thesis. 
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Chapter 1 
Outline of investigation and objectives in this thesis 
The principal aim of the study is to determine whether the entrapment 
of doxorubicin in liposomes results in decreased myocardial damage with 
preservation of the antitumor effect. 
For a better understanding of liposomes as drug carriers, the 
historical background, the chemistry, and some of the physical aspects and 
applications of liposomes, of interest for the clinician, are reviewed in 
Chapter 2. 
Treatment with doxorubicin may eventually result In cardiomyopathy. 
The working mechanisms of doxorubicin are, therefore, given in more detail 
in Chapter 3. Because oxidative processes elicited by doxorubicin are 
thought to be responsible for the toxic effects on the heart, the chemistry 
of oxidative processes elicited by doxorubicin is explained. The relation 
of these processes to cardiomyopathy and other doxorubicin induced toxicity 
is discussed. Lines of investigations on possible ways to protect the heart 
against the detrimental effects of doxorubicin, other than entrapment into 
liposomes, are mentioned. 
In order to correlate and to interprete the results of treatment with 
doxorubicin entrapped in liposomes measurement of plasma levels and tissue 
levels were thought to be necessary. Therefore, a method, which enables 
measurement in microvolumes has been developed (Chapter 4). 
The IgM immunocytoma bearing Lou/M Wsl rat is used for the studies in 
this thesis. This model is described In Chapter 5. 
Preliminary studies had shown that male and female Lou/M Wsl rats had 
different susceptibility for the toxic effects of doxorubicin. Nephropathy 
in male rats was more severe than in female rats. Therefore a time course 
study on the development of nephropathy and cardiomyopathy in male and 
female Lou/M Wsl has been performed, at the same time addressing the 
question whether the consequences of the nephropathy contribute to the 
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development of cardiomyopathy (Chapter 6). 
Next the effect of encapsulation of doxorubicin in positively and 
negatively charged liposomes on cardiotoxlcity, nephrotoxicity and 
antitumor activity in comparison to treatment with free doxorubicin has 
been investigated (Chapter 7). 
Because doxorubicin entrapped in negatively charged liposomes appeared 
to have advantages compared to treatment with free doxorubicin with regard 
to nephrotoxicity and cardiomyopathy and has been found to have antitumor 
activity comparable to free doxorubicin, the effect of entrapment of 
doxorubicin in negatively charged liposomes on suppression of bone marrow 
activity, which is in daily clinical practice one of the major short term 
doxorubicin toxicities, has been studied (Chapter 8). 
The thesis concludes with Chapter 9 where the results are discussed 
together with possible lines of future research in animal tumor systems and 
in clinical practice. 
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Chapter 2 
Introduction to liposomes 
2 .0 Therapeutic index 
The administration of a drug results in several effects, which 
can be divided into desired and undesired ones. The former justify 
the application of chemical agents affecting life processes; the 
latter are defined as toxicity. It belongs to the task of the 
physician to consider whether his patient will benefit from a drug. 
In general, the dosage of a drug necessary for its therapeutic 
effect is required to be several fold lower than for its toxic 
effects. The ratio between the dose which results in the 
therapeutic effect, and the dose which elicits toxic effects, is 
called the therapeutic index. 
2.1 Approaches to increased therapeutic index 
Most of the currently available antitumor drugs are 
characterized by a delicate balance between desired effect and 
toxicity. Whereas in other fields of medicine bone marrow 
depression, gastrointestinal toxicity, mucositis, alopecia, renal 
dysfunction, liver cell damage, pulmonary fibrosis, and 
cardiotoxicity would prohibit the use of a compound, in oncology 
these side effects are (still) accepted as a necessary evil. 
There are several possible lines of research attempts which 
are used to increase the therapeutic index. 
The first approach uses drugs with known efficacy as starting 
point for attempts to improve the balance between the therapeutic 
goal and side effects. Chemical engineering on existing drugs 
results in so called analoga; these are specially designed, 
preferably using knowledge about structure-activity relationships. 
Doxorubicin, a structural analog of daunorubicin, was discovered 
after selecting a mutant of the daunorubicin producing 
microorganism. Nowadays, quite a family of rationally designed 
analogs, e.g. 4'-epidoxorubicin, deoxydoxorubicin, and 4-
demethoxydaunorubicin, is entering clinical trials (Casazza 1978). 
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The second possibility to increase the therapeutic index is 
brought about by alternative routes of administration. For example, 
5-fluorouracil (Ansfield, 1976; Grage 1979), doxorubicin (Haskell, 
1974), cisplatin (Calvo, 1980), and methotrexate (Carter, 1977) 
have been administered intraarterially instead of intravenously in 
order to obtain high levels of cytostatic drug in tumor tissue. 
Intraperitoneal administration of a cytostatic drug is based on the 
pharmacokinetic rationale that an intraperitoneally localized tumor 
may be exposed to very high local drug concentrations, while at the 
utmost systemic levels equal those normally encountered in 
intravenous therapy. Currently, the intraperitoneal administration 
of cisplatin is being studied for ovarian cancer (Howell, 1982; 
1984; McVie, 1985). 
The third way to increase the therapeutic index is based on 
the application of knowledge about the mechanism of drug activity, 
pharmacokinetics, and cell kinetics, resulting in a rationally 
designed dosage schedule. Continuous infusion of S-phase specific 
drugs, e.g. methotrexate and cytosine arabinoside, may increase 
therapeutic effectiveness, because more of the dividing cells, 
reach the S-phase, and are exposed to the steady state serum drug 
level. 
Drug carriers are the fourth method for increasing the 
therapeutic index in cancer chemotherapy. In particular, liposomes 
as drug carriers have been the subject of study on their possible 
role in modifying drug behavior (Weinstein, 1984; Weinstein and 
Leserman, 1984). 
The theoretical arguments for their use are: 1) prolongation 
of drug effect due to prolonged circulation of encapsulated drug; 
2) targeting of liposomes into particular organs by their physical 
properties; 3) targeting of liposomes by attaching an antibody or 
other ligand; 4) targeting of liposomes to the mononuclear 
phagocytic system (MPS); 5) confinement of intact liposomes to an 
anatomical compartment, e.g. the peritoneal cavity; 6) protection 
of a drug from metabolism and immune attack; 7) reduction of drug 
toxicity in tissues which do not accumulate liposomes; 8) the 
physical properties of liposomes may result in the selective local 
release of drug by controlling local temperature or pH; 9) 
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bypassing cell membrane related drug transport systems. 
2.2. Liposomes: Definition and historical background 
Liposomes are microscopic structures consisting of one or more 
concentric lipid bilayers enclosing an equal number of aqueous 
spaces (Weinstein and Leserman, 1984). 
The discovery of the fundamental structure of biological 
membranes and the availability of phospholipids have led Bangham 
and coworkers (1964) to investigate the effects of hydration of dry 
purified phospholipids of cellular origin (Bangham, 1964). They 
demonstrated that the structures which were formed by hydration of 
the aforementioned phospholipids were compatible with closed 
systems, because they behaved like osmometers. In addition, the 
bilayer structure of the leaflet has been shown, which separates 
each aqueous compartment from its neighbour (Bangham, 1964, 1967). 
Initially, these structures were used for the fundamental research 
on membrane structure. Later on, the ability to entrap water 
soluble or lipophilic compounds into the aqueous or phospholipid 
compartments respectively, gave rise to the idea to use liposomes 
as drug carriers. 
2.3. Chemistry and physical properties 
Lipids consist of a hydrophilic headgroup and a lipophilic 
hydrocarbon tail. The degree of water solubility determines the 
behavior of lipids in water or in aqueous solutions: preponderance 
of the headgroup gives rise to micelles, in which the hydrocarbon 
chains extend inward and the head groups outward (Weinstein and 
Leserman 1984); preponderance of the hydrocarbon tails results in 
structures in which the head groups face an aqueous center 
(inverted micelles), or prevents hydration at all. The case where a 
balance between the hydrophilic head group and the hydrophobic 
hydrocarbon chains occurs, bilayers are formed, in which the 
hydrophobic chains face each other and the hydrophilic head groups 
face outwards in the aqueous phase. The lipids which form bilayers 
have characteristically two hydrocarbon chains. Such lipids are: 
phosphatidylcholines (more commonly named lecithin) (PC), 
phosphatidylglycerols (PG), phosphatidylserines (PS), 
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sphingomyelines (SM), and phosphatidylethanolamines. The lipids are 
classified by their head group, whereas in each class the length 
and the degree of saturation of the hydrocarbon chain varies. 
The electrical charge of bilayer membranes is defined in vitro 
at pH 7. One discerns neutral, negatively and positively charged 
bilayer membranes. A negative charge is provided by incorporation 
of phosphatidylserine, phosphatidylinositol, phosphatidic acid, 
phosphatidylglycerol, or dicetylphosphate. Incorporation of 
stearylamine provides a positive charge. 
Each hydrated pure lipid species is characterized by a 
liquid-crystalline transition temperature, at which the lipid 
chains undergo an endothermic change in state from a quasi-
crystalline order to one in which the alkyl chains have more 
motional freedom. The permeability of phospholipid membranes has 
been shown to increase at transition temperature (Blok, 1976). 
Designing liposomes, consisting of lipids with transition 
temperatures a few degrees above the physiological temperature, 
offers the possibility to induce release of encapsulated drugs in 
selectively heated parts of the body. 
2.4. Methods of preparation 
Liposomes arise when dry phospholipids are brought into 
contact with water. The classical technique to prepare liposomes 
is as follows. Phospholipids are dissolved in an organic solvent 
and put into a pear shaped flask. Under continuous rotation the 
organic solvent is evaporated, resulting in a dry phospholipid film 
on the wall of the flask. Thereafter, the phospholipid film, which 
should be as thin as possible, is hydrated in an aqueous buffered 
solution under shaking. This procedure results in multilamellar 
vesicles (MLV), i.e. vesicles consisting of two or more bilayers 
separated by interlamellar spaces filled with water (Fig. 1). The 
size distribution is quite heterogeneous and varies from several 
hundreds of nanometers to several micrometers in diameter. The size 
distribution can be narrowed down by stepwise extrusion through 
Nucleopore polycarbonate membranes with defined pore sizes (Olson, 
1979). This procedure narrows the particle size distribution by 
removing particles with diameters exceeding the pore size. 
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M u l t i l a m i n a r v e s i c l e 
О Small u n i l a m i n a r vesic le 
О 
Large u n i l a m i n a r vesic le 
мш „ MM 
"Solid" "Fluid" 
Fig. 1. In the upper part of this figure a schematic representation 
of the different types of liposomes is given. Each solid 
line represents a bilayer. In the lower part the bilayer is 
shown in detail, and the transition from the solid state 
into the fluid state is suggested. 
The lower region of particle distribution can be controlled by 
dialysis over polycarbonate membranes with defined pore sizes 
(Bosworth, 1982). The average size of lipid vesicles dispersed in 
water can be determined by dynamic light scattering and turbidity 
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measurements (Chong, 1976). 
It Is possible to prepare liposomes, which consist of 
unilamellar vesicles. These are divided into two groups: small 
unilamellar vesicles (SUV) with a diameter of < 100 run and large 
unilamellar vesicles (LUV) with a diameter of > 100 nm. SUV can be 
prepared from dispersions of MLV by sonication, whereafter they are 
freed from MLV by column chromatography. 
LUV are prepared by injecting phospholipids dissolved in ether 
into the aqueous phase which is warmed above the boiling point of 
ether (Deamer, 1978). The ether vaporizes upon contacting the 
aqueous phase, and the dispersed lipids form unilamellar liposomes. 
A draw-back of this technique is the inability to incorporate 
macromolecules and compounds susceptible for ether. In addition, 
the resulting dispersions are not concentrated. 
A second technique to prepare LUV is known as "the reverse 
phase evaporation technique" and has been described by Szoka and 
Fapahadjopoulos (1978). An aqueous buffer is dispersed into a 
solution of phospholipid(s) in an organic solvent. It is suggested 
that inverted micelles are formed. The organic solvent Is removed 
by evaporation under reduced pressure. In the last stage of the 
procedure inverted micelles desintégrate and form unilamellar 
vesicles. Encapsulation efficiency is high and macromolecules can 
be easily entrapped into the aqueous phase. 
Another method for preparing LUV has been described by 
Fapahadjopoulos (1975, 1978). It is based on the calcium-induced 
fusion of sonicated phosphatidylserlne (PS) vesicles and subsequent 
chelation of calcium by EDTA. This procedure results in the 
incorporation of macromolecules with high efficiency. 
The efficiency of water volume trapping varies among the 
different types of liposomes, and is expressed in ml/mmol. For SUV 
this value is about 0.5 ml/mmol; for MLV 2.5 ml/mmol; for LUV 7 
ml/mmol; and for LUV prepared by the reverse phase evaporation 
technique 14 ml/mmol (Fapahadjopoulos, 1978). 
2.5. Interactions of liposomes with plasma proteins 
Experiments in vivo had shown that some liposomes loose their 
contents very rapidly after intravenous Injection. In vitro 
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analysis of this phenomenon has demonstrated that liposomes are 
attacked by high density lipoprotein (HDL). Transfer of liposomal 
PC into the HDL complex has been shown. In addition, small amounts 
of phospholipids have also been found in very low- and low density 
lipoproteins (VLDL and LDL), probably as a result of phospholipid 
transfer from the HDL complex. 
The susceptibility to HDL attack by vortex-dispersed liposomes 
appears to be maximal at the gel to liquid crystalline phase 
transition temperature. This phenomenon can be used for 
hyperthermic targeting of liposomes. Sonicated liposomes do not 
show such a distinct temperature optimum, which is ascribed to the 
decreased radius of curvature after sonication. Enzymatic activity 
of HDL is hampered by a small radius of curvature. 
The incorporation of cholesterol in the bilayer confers 
structural stability on the liposome. Cholesterol not only 
diminishes the diffusion of a variety of solutes through the 
bilayer membrane, it also reduces the susceptibility towards 
phospholipase action (Weinstein 1980, Yatvin 1981). 
Human serum albumin is known to be adsorbed onto the outer 
surface of liposomes. Such human albumin-coated liposomes evoke a 
strong immune response in rabbits, leading to the rapid formation 
of high anti-human serum albumin titers. A detrimental effect on 
the integrity of liposomes has not been proven for the adsorption 
of albumin to liposomes. Albumin, as well as alpha-, beta- and 
gammaglobulins in vitro have been shown to Interfere with 
liposome-cell interaction. The implications of these in vitro 
observations for the in vivo behavior of liposomes are not clear. 
A concise review on the interaction of liposomes with plasma 
proteins is given by Scherphof et al. (1981). 
2.6. Theoretical considerations on liposome cell Interaction 
Cells can interact with liposomes in four different ways 
(Pagano, 1978) : 
1) Stable adsorption 
2) Endocytosis 
3) Fusion 
4) Lipid transfer/exchange 
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The possible mechanisms are schematically represented in fig. 2. 
Stable adsorption Endocytosis 
Г , 
transfer 
> 
Fig. 2. Schematic representation of liposome-cell interaction 
(after Pagano 1978). 
1. Stable adsorption is the association of intact liposomes 
with the cell surface without their internalization. The adsorption 
may be mediated by nonspecific forces, e.g. electrostatic forces or 
by specific components (e.g. surface receptors, antibodies). 
2. Endocytosis is the uptake of intact liposomes into 
endocytotic vesicles. In general, endocytosis leads to delivery to 
the lysosomal apparatus. 
3. Fusion is the merging of the lipid bllayer (the outermost 
bilayer of a MLV) with the plasma membrane and concomitant release 
of liposome contents into the cytoplasmic space. Leakage of 
liposome contents into the medium during the fusion event is 
possible. Secondary processes may concentrate the vesicle contents 
Fusion 
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from the cytoplasma within other intracellular compartments (e.g. 
lysosomes). In the case of fusion of a MLV with a cell, a 
multilamellar form with one bilayer less than the original should 
be found in the cytoplasm. 
4. Lipid transfer/exchange is the transfer of lipid molecules 
between liposomes and cells without cell association of aqueous 
liposome contents. 
Experimental criteria for distinguishing various mechanisms of 
liposome-cell interaction have been described by Pagano (1978). 
2.7. Liposome-cell interactions in vitro 
The uptake and processing of liposomes by rat liver 
macrophages have been extensively studied in vitro in chemically 
defined media (Dijkstra, 1983). Endocytosis was found to be the 
predominant uptake mechanism for negatively charged LUV and neutral 
vesicles, whereas about one half of positively charged vesicles 
remained adsorbed at the cell surface. The attachment of liposomes 
appeared to be dependent on the presence of divalent cations, in 
particular Ca . Clues have been found that the binding site on the 
Kupffer cell is identical for positively charged and neutral 
liposomes, and differs from the binding site for negatively charged 
liposomes. After endocytosis of negatively charged LUV the 
radioactive marker of the aqueous compartment appeared in the 
incubation medium almost completely, whereas only 30% of the 
radioactive marker of the lipid compartment was released into the 
incubation medium. These effects were inhibited by ammonia and 
chloroquine, inhibitors of lysosome activity. After intralysosomal 
degradation of liposomes endocytosed by Kupffer cells the choline 
moiety of phosphatidylcholine or sphingomyelin was found to be 
reutilized for de novo synthesis of cellular phosphatidylcholine. 
Human leukocytes have shown to take up MLV in whole blood in 
vitro (Kuhn, 1983). Human peripheral blood monocytes, cultured in 
vitro, take up liposomes intactly, negatively charged ones more 
rapidly than positively charged or neutral vesicles (Mehta, 1982). 
2.8. Clearance and distribution of liposomes in vivo 
Size and surface charge of liposomes are two of the major 
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determinants of liposome clearance (Juliano, 1981). SUV with 
diameters of 20-50 nm have been found to persist longer in the 
circulation than MLV with diameters of ca. 1000 nm of the same 
composition. The clearance rate of liposome samples, homogeneous in 
size, can be described by a simple exponential function, whereas 
the clearance of heterogeneous samples can only be fitted by a sum 
of exponentials. Negatively charged SUV are more rapidly cleared 
from the circulation than neutral and positively charged ones. 
Intravenously administered liposomes have been reported to be 
removed from the blood predominantly by liver and spleen. In the 
liver large liposomes (> 200 nm) have been found to be almost 
exclusively associated with Kupffer cells (Segal, 1974; Roerdink, 
1981; Poste, 1982). In contrast, liposomes with diameters of 30-100 
nm also have been found in hepatocytes, probably because they are 
able to pass the fenestrae in the endothelial lining of sinusoids 
(Scherphof, 1983). In vivo, In-labelled bleomycin, encapsulated 
in liposomes, injected intravenously in two patients was found to 
accumulate in the liver, as determined by whole-body scanning. This 
radioactivity was found to be concentrated in hepatic lysosomes as 
has been shown in studies on percutaneous liver biopsies, taken 90 
min. after injection (Segal 1975). 
Cytostatics and liposomes 
Incorporation of drugs 
The association of drugs with liposomes is determined by the 
oil-water partition coefficient and by charge (Juliano, 1979). 
Water-soluble drugs are entrapped in the aqueous compartments by 
forming liposomes with an aqueous phase containing dissolved drugs. 
The entrapment efficacy for small molecules approaches the ratio 
between the volume of entrapped aqueous phase and the original 
volume of the aqueous phase. Lipophilic drugs are incorporated into 
the bilayer. Most drugs are amphophilic, resulting in partition 
between the aqueous compartment and the bilayer. 
Methotrexate 
In the mid-seventies the encapsulation of methotrexate (MTX) 
in liposomes has been studied. Because at pH 7.4 MTX is negatively 
charged, liposomes with a positive charge in order to get an 
electrical interaction between MTX and the liposome were used 
(Kimelberg 1976, 1978). A single i.v. injection of MTX entrapped in 
liposomes in Macacus irus resulted in prolonged MTX levels at 4 
hours after administration, compared to free drug. The plasma 
level after i.v. injection of MTX in mechanically disrupted 
liposomes was 6-fold higher at 4 hours than after free MTX, whereas 
the plasma level after administration of sonically disrupted MTX 
containing liposomes was 100-fold compared to the plasma level 
after injection of free drug, pointing at the particle size as a 
determinant of in vivo behavior. In parallel with these findings 
the renal excretion of MTX entrapped in mechanically disrupted 
liposomes was 18% of the renal excretion of MTX after the same dose 
of free MTX, whereas after administration of MTX entrapped in 
sonically disrupted liposomes the renal MTX excretion was 1%. There 
was more than a 160-fold increased uptake of MTX in the spleen 
after administration of mechanically disrupted MTX containing 
liposomes. For sonically disrupted liposomes this ratio was 20. The 
next high tissue levels were found in the liver. Compared to 
Intestinal tissue MTX levels after administration of free drug, the 
levels in intestinal tissue after administration of liposome 
entrapped MTX were low. Similar results were obtained by Colley 
(1975) and Freise et al. (1977). 
With regard to antitumor effect entrapment of MTX in liposomes 
showed no better results compared to treatment with free drug 
(Kimelberg 1978). Other investigators have found increased efficacy 
of liposome entrapped MTX against sensitive and MTX insensitive 
tumors (Kosloski 1978, Kaye 1981, Richardson 1982). 
2.9.3. Cytosine arabinoside 
Entrapment of cytosine arabinoside (Ara-C) in liposomes 
enhanced the in vitro cytotoxic effect against L1210 cells (Mayhew 
1978). This was only found in the case of positively charged 
vesicles. Liposome entrapped Ara-C prolonged survival of mice, 
intraperitoneally inoculated with L1210 (Kobayashi 1975, 1977). In 
parallel with the in vitro studies Kataoka (1978) found an 
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advantage for positively charged vesicles. Mayhew (1978) found no 
difference with regard to charge, however MLV appeared more 
effective than SUV. Entrapment of Ara-C in liposomes resulted in 
prolonged plasma Ara-C levels, and a preferential uptake in the 
liver (Mayhew 1978). The enhancement of the therapeutic effect of 
liposome entrapped Ara-C is thought to be due to protection against 
biodégradation. 
Larger MLV resulted in increased retention of Ara-C in the 
lung (Hunt 1979). Intratracheal instillation of Ara-C entrapped in 
liposomes confined the inhibition of the incorporation of H-
thymidine only into pulmonary tissue (McCullough 1979). 
Actlnomycln-D 
Entrapment of actinomycin-D in liposomes rendered drug-
resistant tumor cells in' vitro susceptible for this drug by 
enhancement of drug uptake (Poste 1976). Treatment of tumor 
bearing mice with liposome encapsulated actinomycin-D prolonged 
their survival compared to treatment with equal dose of the free 
drug (Gregoriadis 1975). In addition, administration of liposome 
entrapped actinomycin-D appeared less toxic to mice (Rahman 1974). 
Actinomycin-D entrapped in the lipid phase of liposomes resulted in 
high actinomycin-D levels in the lungs and low levels in the 
intestinal wall, whereas free actinomycin-D and actinomycin-D 
entrapped in the aqueous phase showed high levels in the intestinal 
wall and low levels in the lungs (Rahman 1975) . 
Non cytostatic drugs and liposomes 
Insulin 
In order to circumvent the inconveniences of daily insulin 
injections, the oral administration of insulin entrapped in 
liposomes has been studied. In diabetic rats orally administered 
insulin entrapped in liposomes lowered serum glucose levels whereas 
non-encapsulated insulin did not (Patel 1976, Tragi 1979). Immune 
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reactive insulin I-insulin could be detected in serum after oral 
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administration of I-insulin in liposomes (Arrieta-Molera 1982). 
Similar results were obtained in rabbits (Arrieta-Molera 1976). 
However, disappointing results were obtained by Shenfield (1982). 
Administration of liposome entrapped insulin to normal man did not 
result in a significant change in blood glucose concentration 
(Patel 1978). 
Instability of insulin containing liposome preparations and 
unpredictable dose response relationship appear to be the major 
impedements for further development of this line of investigation. 
2.10.2. Enzyme replacement 
The treatment of enzyme deficiencies with free enzyme 
encounters the problem of immunological effects, inactivation in 
plasma and interactions with substrates in plasma or on cell 
surfaces of blood elements or tissues. Entrapment of enzymes in 
liposomes is thought to bypass these problems. Uptake of exogenous 
horse-radish peroxidase in phagocytes of Mustelus canis has been 
accomplished by immunoglobulin-coated liposomes (G.Weissmann, 1975, 
1976). Injection of neuraminidase entrapped in liposomes prevented 
the action of this enzyme on substrates in plasma and on blood 
cells, and most of it was recovered from the lysosomal fraction of 
the liver (Gregoriadis, 1974). In vitro treatment of fibroblasts of 
feline Gin gangliosidosis with B-galactosidase encapsulated in 
liposomes resulted in increased B-galactosidase activity and 
increased clearance of glycopeptides, compared with treatment of 
non-entrapped B-galactosidase (Reynolds, 1978). In vitro it has 
been possible to introduce purified placental hexosaminidase A into 
polymorphonuclear leukocytes of Tay-Sachs patients by means of 
immunoglobulin-coated liposomes (Cohen, 1976). In clinical medicine 
liposome-entrapped glucocerebroside B-glucosidase has been used in 
Gaucher disease without a convincing clinical response 
(Gregoriadis, 1982). 
2.10.3. Miscellaneous applications 
Treatment of mice with liposome-encapsulated Amphotericin В 
did not result in abnormalities in blood chemistry and histology 
and a LD50 could not be obtained, in contrast to treatment with 
free Amphotericin B. The encapsulated drug was as effective as free 
drug in the treatment of Candida albicans, altogether resulting in 
an improved therapeutic index (Lopez-Berestein, 1983). 
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Entrapment of drugs In liposomes has been proposed for the 
enhancement of local drug concentrations and the restriction of 
drug effects to the area to be treated In topical drug applications 
In ophthalmology and dermatology (Schaeffer, 1982, Mezel, 1982). 
The application of liposome entrapped triamcinolone acetonide to 
rabbit skin resulted in higher triamcinolone acetonide 
concentrations in epidermis and dermis and lower concentrations in 
blood when compared with the classical way of application. Lectin-
mediated attachment of liposomes to cornea enhanced the 
transcorneal flux of entrapped carbachol across isolated rabbit 
corneas under conditions of continuous tear flow. 
The encapsulation of hemoglobin in liposomes has been 
suggested in order to circumvent incompatibilities in blood group 
serology (Gaber, 1983). 
Succesful removal of iron and plutonium has been described 
after administration of metal chelators entrapped in liposomes in 
mice (Rahman, 1975b, Rosenthal, 1975, Lau, 1983). 
ImmunoloRlcal aspects 
The phospholipids used in the majority of studies on liposomes 
encapsulating anticancer drugs are usually thought to be of low 
antigenicity. The administration of N-dinitrophenyl 
phosphatidylethanol-amines inserted into liposomal membranes has 
been shown to raise antibodies (IgM and IgG) in the guinea pig 
(Uemara 1975). In addition, glycolipids, lipid A (the lipid 
component of bacterial lipopolysaccharide), and several anionic 
phosphoglycerides have shown antigenicity when injected as 
constituents of liposomes (Alving 1977). Furthermore, rabbits 
develop antibodies not only against lipid A but also against 
phosphatidylcholine, when injected with lipid A inserted liposomes 
composed of phosphatidylcholine (Schuster, 1979). 
Not only insertion of antigens into the bilayer membrane, but 
also entrapment of antigen in the aqueous phase In liposomes or 
binding to liposomal surface gives rise to antibodies (van Rooyen 
1977, 1983). Liposomes have been suggested as adjuvants for 
vaccination. 
Positively charged liposomes, containing dirayrlstoyl 
phosphatidylcholine, cholesterol and certain glycolipids, have been 
shown to activate the alternative complement pathway in vitro 
(Cunningham 1979). 
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Chapter 3 
Introduction to doxorubicin 
3.1. OriRin and chemistry 
Doxorubicin belongs to the anthracyclines, members of the 
rhodomycin group, which are produced by Streptomyces species. 
Doxorubicin is extracted with a mixture of acetone and aqueous 
sulfuric acid from colonies of Streptomyces peucetius var. caesjus 
(Arcamone 1969). Doxorubicin (- 14-hydroxy-daunorubicin) might be 
considered as an analog of daunorubicin. 
Anthracyclines are composed of a tetracyclic chromophore 
linked to a sugar. The general structure is shown in fig. 1. The 
anthracycline structure is responsible for their behavior as 
fluorescent compounds. 
Fig. 1. On the left side the general structure of anthracyclines is 
shown. The right side represents the structure of 
doxorubicin. 
3.2. Analytical methods 
The fluorescent characteristics of these compounds have 
enabled the development of relatively simple assay methods. The 
measurement of total fluorescence of an extract of tissue or plasma 
was the first technique used (Schwartz 1973). The development of 
thin-layer chromatography enabled the detection of several 
37 
metabolites (Chan 1979). Adequate separation of metabolites is also 
a feature of high performance liquid chromatography, which is 
nowadays commonly used because it is less expensive and less 
laborious than thin layer chromatography (Israel 1978, Eksborg 
1979, Oosterbaan 1984). The cellular uptake of doxorubicin has 
been studied by flow cytometry (Sonneveld 1981, Durand 1981, 1981a, 
Speth 1985). 
Pharmacokinetics 
Plasma doxorubicin clearance curves after intravenous bolus 
administration are triphasic, with half-lives of 8-25 minutes, 
1.5-10.0 hours, and 24-48 hours, respectively (Myers 1982). 
Doxorubicin binds to a considerable extent to plasma proteins and 
to tissue sites. The major metabolite, among others, is 
doxorubicinol, which also has some antitumor activity. Doxorubicin 
is metabolized to doxorubicinol predominantly in the liver by 
aldo-ketoreductases. These enzymes are also present in peripheral 
blood cells which has implications for the handling of blood and 
plasma samples (Eksborg 1981). Biliary excretion of doxorubicin is 
the most important way of elimination. The renal excretion of 
doxorubin in man has been found to be insignificant (Benjamin 
1973). 
Range of activity 
Doxorubicin is one of the major drugs in clinical oncology. It 
is active against acute leukemias, malignant lymphomas, breast 
cancer, sarcomas, ovarian cancer, gastric cancer, and small cell 
lung cancer. In addition, doxorubicin is instilled locally in the 
urinary bladder for the treatment of superficial bladder cancer. 
Mechanisms of action 
Four biochemical events are thought to play a role in the 
biological effects of doxorubicin. These are: 
1. DNA binding 
2. free radical formation 
3. metal chelation 
4. membrane effects. 
The relationship between these events is very complex and the 
contribution to the eventual biological effects is not known for 
each event separately. A detailed review of the biochemical 
background and mechanisms is beyond the scope of this thesis. For a 
detailed and updated review of this complicated, but very exciting 
matter, the reader is referred to Myers (1979, 1980, 1981, 1982, 
1982a, 1983, 1984). 
The major points will be reviewed in the following paragraphs. 
3.5.1. DNA binding 
Doxorubicin intercalates DNA with subsequent effects on DNA 
and RNA synthesis and DNA damage. The tetracyclic chromophore 
inserts itself between base pairs perpendicular to the long axis of 
the double helix, the major interaction coming between the В and С 
rings of doxorubicin and the bases above and below them. Cells have 
been shown to proliferate from Gl- through S- to G2-phase despite 
the presence of doxorubicin. 
3.5.2. Free radical formation 
A free radical is a compound with one unpaired electron. In 
the presence of NADPH, microsomal P450 reduces doxorubicin to its 
semiquinone radical. In the presence of oxygen the seraiquinone 
radical transfers the unpaired electron to yield the superoxide 
radical. This radical is dismutated to hydrogen peroxide, which 
subsequently reacts with superoxide to form the hydroxyl radical 
(OH-)· In overview: 
(1) 20¿" + 2H+ — H 20 2 + 0 2 
(2) 0 2 _ + H J O J — • OH' + OH - + 02 
The hydroxyl radical is one of the most reactive substances known 
and is able to attack pyrimidine and purine bases, thiols and 
amines. The superoxide radical damages cell membranes and causes 
cleavage of DNA. 
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5.3. Metal ion chelation 
Doxorubicin chelates zinc, copper, and iron. In particular the 
chelation of iron seems to have major implications. Equation (2), 
described in the former paragraph is thought to be catalyzed via 
the following mechanism: 
(3) Oj + Fe 3 + -02 + Fe 2 + 
(4) Fe 2 + + H J O J — - OH" + 0H~ + Fe 3 + 
So, the transfer of electrons is enhanced in the presence of iron 
or its chelate. 
5.4. Membrane effects 
Doxorubicin has been found to bind to erythrocyte membranes 
and to cause altered membrane morphology and lysis. Of all cell 
membrane phospholipids, doxorubicin binds most tightly to 
cardiolipin. The highest cardiolipin concentrations are found in 
mitochondrial membranes, in particular the inner leaflet. 
6. Toxicity 
6.1. Cardiotoxicity 
Soon after the introduction of daunorubicin into the treatment 
of acute leukemias of childhood, it became apparent that this drug 
was associated with the development of heart failure. Subsequently, 
also doxorubicin, which has a wider range of application in 
comparison to daunorubicin, appeared to induce myocardial damage. 
The incidence of clinical overt heart failure has been found to 
increase sharply above a cumulative dose of 550 mg/m . An increased 
incidence of anthracycline-induced cardiomyopathy has been 
identified after radiation therapy of the mediastinum and in 
patients with hypertension. 
Clinically, anthracycline-induced cardiomyopathy is 
characterized by forward and backward failure. Although improvement 
of heart failure has been observed, the prognosis is, in general, 
bad: the mortality rate can be as high as 50%. 
Free radical formation with subsequent oxidative damage is 
thought to be the major mechanism of cardiomyopathy. In particular, 
because the cardiac tissue of some species has been shown to lack 
catalase, which eliminates hydrogen peroxide. In addition, 
doxorubicin destroys glutathione peroxidase (Doroshow 1980, Revis 
1978). As a consequence, two major enzymes involved in the 
detoxification of hydrogen peroxide, are lacking in the heart, at 
the very moment that the production of hydrogen peroxide is 
stimulated by doxorubicin. 
The membrane effects, described earlier, may result in 
membrane damage, which has detrimental effects on calcium-handling. 
In the heart muscle contractility force is regulated by governing 
2+ Ca concentrations. 
Although in the past decennium many, often very sophisticated, 
studies on the biochemical backgrounds of anthracycline toxicity 
have been performed, a clear picture has not yet evolved. 
Other toxicities 
Myelosuppression is the dose limiting toxicity of doxorubicin 
in everyday practice. Leukocyte and thrombocyte count reach their 
nadir 7 to 10 days after administration, and their counts return to 
normal levels within 21 days after injection. 
Alopecia is an unevitable consequence of treatment with 
doxorubicin. Rarely, mucositis is encountered. 
In contrast to cardiotoxicity, the other toxic events can 
readily be explained by the inhibition of the proliferative 
activity of bone marrow, hair root, and gastrointestinal mucosa. 
Lines of investigation on cardioprotection 
Because there were strong indications that oxidative damage 
was the principal cause of cardiomyopathy, early in anthracycline 
research attempts have been made to prevent cardiomyopathy by 
anti-oxidants or "radical-scavengers" (Myers 1977). Among these are 
alpha-tocopherol, N-acetylcysteine and carnitine (Sonneveld 1978, 
Wang 1980, Van Vleet 1980, Mimnaugh 1979, Breed 1980, Freeman 
1980). No consistent results have been obtained. 
With regard to the role of iron as a catalyst in the oxidative 
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avalanche the possible role of EDTA-derived chelating compounds 
ICRF 187 and ICRF 159 as protector have been investigated (Herman 
1981, Herman 1983, Guilani 1981). 
The development of analoga is another line of research 
(Arcamene 1985). 
For the clinician variations of the dosage schedule are the 
obvious way to make an attempt to avoid cardiotoxicity (Weiss 1976, 
Chlebowski 1980, Legha 1982, 1982a). 
The entrapment of doxorubicin in liposomes has resulted in 
reduction of cardiotoxicity in animal models (Rahman 1980, 1981, 
Olson 1982, Gabizon 1982, Forssen 1981, 1983). 
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ANALYSIS OF ADRIAMYCIN AND ADRIAMYCINOL IN MICRO VOLUMES OF RAT PLASMA 
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Q.G.C.M. van Hoesel 
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Despite ten years of intensive investigation into the therapeutic 
effects and side-effects of the anthracycline derivative adriamycin, 
cardiac toxicity is still one of its most severe toxic effects. This limits 
the dose and consequently its application in cancer chemotherapy. As part 
of an investigation of the cardiac toxicity caused by adriamycin in tumor-
bearing rats, pharmacokinetic data were needed to find out whether there is 
a correlation between histological changes of heart tissue, the dose of 
adriamycin and the method of administration. Hence, an assay for adriamycin 
and its active metabolite adriamycinol was needed to establish 
pharmacokinetic parameters, such as peak levels, rate of distribution and 
elimination. If several rats are used for one test, the results due to 
interindividual differences will not be reliable. Therefore, we decided to 
establish pharmacokinetic parameters for one single rat. 
From the literature (1, 2) one can conclude that after the initial 
distribution phase, a biphasic disappearance pattern is to be expected. 
Therefore, 10-15 plasma samples are needed to obtain a complete plasma 
concentration disappearance curve. This limits the volume of the plasma 
samples to be analyzed to a maximum of 100 ul (the total blood volume of a 
rat is 4-6 ml). 
Recently described high-performance liquid chromatographic methods 
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that involve fluorescence detection for selective determination of 
adriamycin and adriamycinol, are preferred to non-selective methods like 
total fluorescence analysis (3,4 ) and radio-immunoassays (A, 5). 
Reversed-phase (6-11) as well as straight-phase (12-14) methods can be 
used. With straight-phase liquid chromatography and gradient elution, one 
can analyse nearly all the metabolites, including the inactive aglycones, 
glucuronated and sulphonated metabolites. Reversed-phase liquid 
chromatography can easily be applied for the selective assay of adriamycin 
and its active metabolite adriamycinol. If these methods are to be applied 
successfully in pharmacological practice, further requirements are easy 
sample treatment and simple apparatus; gradient elution techniques, for 
instance, should be omitted if possible. 
adriamycin R=-C-CH20H 
OH 
ι 
adriamycinol R = -C-CH20H 
¿ H \ daunorubicm К=-С-СНз 
OH\ / 
In this paper, a simple and selective high-performance liquid 
chromatographic method involving fluorescence detection is described. Rat 
plasma samples each with a volume of 100 ul were used, plasma levels being 
within the therapeutic range. 
To test the applicability of this method in pharmacological practice, 
plasma disappearance curves and preliminary pharmacokinetic data for 
several rats have been determined. A typical plasma concentration-time 
curve and related pharmacokinetic data are presented. 
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EXPERIMENTAL 
Chemicals and apparatus 
Adriaraycin-HCl was obtained from Farmitalia in vials of 10 mg with 50 
mg lactose. Farmitalia kindly gave us samples of adriamycinol. 
Daunorubicin-HCl was obtained from Specia in vials of 20 mg with 100 mg D-
mannitol. Chromatographic solvents and other chemicals were of analytical 
grade and were used without further purification. The chromatographic 
system consisted of a Model 6000A solvent delivery system and a U6K 
septumless injection system (both from Waters Assoc, Milford, MA, U.S.A.), 
and a Perkin-Elmer Model 204 fluorescence detector supplied with a Hellma 
25-μ1 flow cell (Hellma, type 176.70). A Merck LiChrosorb RP-8 (50432 C8) 
reversed-phase column (125 χ 4 mm I.D., particle size 5 tim) was used. The 
mobile phase consisted of acetonitrile-distilled water-0.1 M Н^РОл 
(31:61:8) containing 10 tig desipramine-HCl per ml (pH 2.3), and was 
filtered through a 0.2-fim filter and deaerated ultrasonically before use. 
The flow-rate was 1.5-2 ml min" . Fluorimetrie detection was performed at 
excitation wavelength 470 nm and emission wavelength 565 nm. Quantitation 
was based on peak height ratios using the structural analogue daunorubicin 
as an internal standard. The chromatographic analyses were performed at 
ambient temperature. 
Sample pre-treatment of micro-volumes of rat plasma 
The rats received i.v. injection of adriamycin. By cannulating the 
vena jugularis, heparinized blood samples of about 200 ul were collected in 
polypropylene tubes over a period of 3 days. The samples were centrifuged 
immediately and stored at -20oC prior to analysis. For the extraction of 
adriamycin and adriamycinol, 100 fil plasma was mixed with 100 fil borate 
buffer pH 9.0 in a conical polypropylene tube of 1.5 ml. The buffer was 
composed of 24.7 g boric acid, 6.8 g sodium hydroxide, 29.7 g potassium 
chloride and 10 mg desipramine-HCl per litre (7, 15). Appropriate amounts 
of the internal standard daunorubicin were added in 10-fil volumes of an 
aqueous solution. A 0.5-ml volume of a chloroform-1-heptanol mixture (1:1) 
was added. The mixture was vortexed for 45 sec and centrifuged for 5 min at 
2500 g. The aqueous upper layer was removed and the organic layer was 
transferred to a new conical polypropylene tube of 1.5 ml containing 100 |jl 
0.2 M phosphoric acid. After 1 min vortexing and 5 min centrifugation at 
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2500 g, 10 to 90 |il of the aqueous phase, depending on the expected 
concentration level, was injected into the chromatographic system. All the 
glassware used was silanized before use by treating it with a solution of 
2* trimethylchlorosilane in toluene, followed by a washing procedure with 
methanol. 
Blood sampling 
Male Vistar rats all weighing about 250 to 300 g were cannulated in 
the left vena jugularis. The cannule was flushed with a heparin solution 
twice a day and after each blood sampling. Adriamycin (2 mg.kg" ) was 
administered by i.v. bolus injection. The valve of the cannule was opened 
and about 200 jil blood was collected in heparinized polypropylene tubes. If 
the rats damaged the cannule, blood was collected by orbital puncture. 
Calculation 
The plasma levels of adriamycin were analysed using the HP 9810, 
programmed with the Wagner stripping method (16). 
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RESULTS 
The straight-phase liquid chromatographic method for the analysis of 
adriamycin and adriamycinol, described by Baurain et al. (14), is the only 
one that uses 100 ul of plasma. However, the authors showed its 
applicability in the |ag range only. All other methods mentioned earlier in 
this paper, reversed-phase as well as straight phase, need 1-4 ml of 
plasma. 
To determine adriamycin and adriamycinol in the ng range, with 
acceptable accuracy, using 100 jil of plasma, special techniques have to be 
developed to prevent loss of adriamycin and adriamycinol, because of their 
strong adsorptive properties. The flexibility of the sample pre-treatment 
is limited by the adsorptive properties. Polypropylene tubes should be used 
if possible; if glassware is used it should all be silanized (17). However, 
even with silanized or siliconized glassware, adriamycin may still be 
adsorbed from an aqueous solution. Desipramine-HCl, with comparable 
adsorptive properties, was added to the buffer in the extraction procedure 
and to the mobile phase in the chromatographic procedure, in order to 
decrease the number of active, adsorptive sites. The syringe was pre-
treated with trimethylchlorosilane for the same reason and had to be washed 
with a 4M hydrochloric acld-methanol mixture (1:9). The syringe was washed 
many times with water between each injection, to prevent memory effects 
appearing on this trace level analysis. The optimum pH value of the buffer 
mixed with plasma was found to be pH 9.0. Eksborg (18) mentioned pH 8.6 as 
an optimum, but he used an organic extraction solvent with a different 
composition. 
As in several other investigations (9, 11, 13) the structural analogue 
daunorubicin was used as internal standard for comparable lipophilicity, 
and for comparable chemical and fluorescence properties. We found 
chloroform-1-heptanol (1:1) to be the best possible composition for the 
extraction of adriamycin, adriamycinol and daunorubicin (15). Using this 
organic solvent in a phase-volume ratio of 1:5, we achieved a 95% recovery 
of adriamycin for the whole clean-up procedure. 
Eksborg (6, 17) determined the influence of the pH and the composition 
of the extraction mixture. His results indicate that an adriamycinol 
recovery of about 90% can be expected under these circumstances; this was 
confirmed in practice. 
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It is important to vortex the mixture of plasma and buffer for 45 sec 
since longer vibration yields in a smaller usable organic layer, because of 
a kind of emulsion of precipitated protein which is formed in the organic 
solvent. In order to achieve an almost quantitative transfer of adriamycin 
and adriamycinol to a small volume of the aqueous phase, the aqueous layer 
must be kept at an acidic pH. 
By using 0.2 M H.jP04 in the aqueous phase, we obtained quantitative 
recovery and negligible aglycone formation. When aqueous, acidic solutions 
are stored for longer than about 3 h before analysis, it is preferable to 
use 0.1 M НтРОд, despite its lower yield. Also the life-time of the column 
will increase if the pH is increased. 
Eksborg compared several chemically bonded phases for optimum 
separation of the drug, metabolite and plasma peaks and recommended the use 
of RP-8 bonded phases. 
We investigated several commercially available RP-8 columns and 
selected the RP-8 column from Merck because of its very small plate height. 
The composition of the mobile phase (acetonitrile-water-0.1 M HjPO^, 
37:60:3) was optimized for this column. For other types of columns the 
composition had to be changed for maximum separation. To prevent aglycone 
formation during the chromatographic process, the concentration of 
phosphoric acid should never exceed 0.1 M. The capacity factors (k') of 
adriamycin, adriamycinol and daunorubicin proved to be 1.7, 0.7 and 5.7, 
respectively, under these circumstances. 
As in the sample treatment, the strong adsorptive properties of 
adriamycin interfere with the injection system and disturb the 
chromatographic processes and detection. Addition of desipramine-HCl 
diminishes this interference to a large extent. 
In this procedure no gradient elution is needed; for routine analysis 
the flow-rate was kept at 2 ml min" to obtain short analysis times. Fig 1 
shows a chromatogram of the analysis of a rat plasma sample. Calibration 
curves for standard solutions of adriamycin in aqueous solution were linear 
over the studied concentration range from 0.1 ng/100 yl to 10 fig/lOO ul and 
passed through the origin (r - 0.9999). Standard deviations in replication 
measurements were 1.5% in the higher range, and 3% in the lower range. 
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daunorubicin 
adriamyLin 
Fig. 1. A chromatogram of the analysis of rat plasma. Left, blank rat 
plasma; middle, blank rat plasma, spiked with 40 ng adriamycin/100 
•pi; right, plasma of treated rat, spiked with 60 ng 
daunorubicin/100 ul. 
Calibration curves for the analysis of spiked plasma samples were 
linear over the studied concentration range of 1 ng/100 ul plasma up to 100 
^ig/100 .pi plasma and passed through the origin (r - 0.9999). Standard 
deviations in the analysis of plasma samples were 3% in the higher range, 
and 8% in the lower range. 
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PRELIMINARY PHARMACOKINETIC RESULTS IN RATS 
We have developed the described assay of adriamycin in rat plasma in 
order to investigate the relation between the dosage, the method of 
administration of adriamycin and the toxic effects on heart tissue. To 
investigate the reliability of the method in pharmacological practice, we 
established the plasma concentration-time curves for several rats, on the 
basis of very small volumes of rat plasma The blood samples were collected 
according to the procedure described in the experimental chapter, namely by 
cannulating the vena jugularis. If the rats "disconnected" the cannule, 
blood samples were collected by orbital puncture. 
Fig. 2. A typical log plasma concentration-time curve for one rat 
(adriamycinol could only be analysed for up to 10 h). 
Table 1. 
TYPICAL PHARMACOKINETIC DATA FOR THE ANALYSIS OF ADRIAMYCIN OF 
THE log PLASMA CONCENTRATION-TIME CURVE FROM FIG 2 
WlsCar rat, 267 g, 2 mg adrlanycIn/kg by i ν bolus injection 
С 
A 
В 
Ρ 
. -at . -3t 
- A«e + B-e 
996 6 ng ml'1 
99 6 ng ml"1 
7 8 ng ml"1 
+ 
a 
8 
Ύ 
Ρ .Γ
Η 
5 17 h"1 
1 12 h"1 
0 020 h"1 
\ 
C1
rn 
- 34 3 h 
- 149 1 kg"1 
- 0 050 1 min k g · 1 
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A typical plasma concentration-time curve for adriamycin and 
adriamycinol is shown in Fig. 2. The line, shown in this figure, is the 
best fit, as calculated by the computer program. The pharmacokinetic data, 
calculated using this computer program, are collected in Table I. A three-
compartment model gave the best fit. This highly sensitive method makes it 
possible to measure 6-8 half-lives. The pharmacokinetic data found in this 
way give new insight into the distribution and elimination of the drug. The 
distribution volume (V γ ) , the half-life time of the elimination phase (t 
1/2 χ) and the total body clearance (CLt t ) are remarkably large, compared 
to earlier published data (19, 20). Further pharmacological experiments are 
in progress. 
It can be concluded that the method described in this paper is 
reliable, sensitive and easy to use in pharmacological practice and may 
give us further insight into the pharmacology of adriamycin and its active 
metabolite in the rat and other species. 
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ABSTRACT 
Antitumor activity, cardiotoxicity and nephrotoxicity induced by 
doxorubicin were studied in LOU/M Wsl rats bearing a transplantable solid 
IgM immunocytoma. Animals with a tumor (diameter 15.8 ± 3.3 ram) were 
treated with i.v. injections of doxorubicin on five consecutive days, 
followed by one weekly injection for 7 weeks (dosage range from 0.015 - 4.0 
mg/kg body weight). Tumor regression was observed with 0.5 mg/kg. Complete 
disappearance of the tumor was induced with 1.0 mg/kg. Histologic evidence 
of cardiotoxicity scored as grade III was only observed at a dose of 1.0 
mg/kg. Light microscopic evidence of renal damage was seen above a dose of 
0.5 mg/kg, which resulted in albuminuria and very low serum albumin levels. 
In the 1.0 mg/kg group the serum albumin level decreased from 33.6 ± 4.1 
g/1 to 1.5 ± 0.5 g/1. Ascites and hydrothorax were observed 
simultaneously. The same experiments were carried out with non-tumor-
bearing rats, in which no major differences were observed. 
In conclusion, antitumor activity, cardiotoxicity and nephrotoxicity 
were studied simultaneously in one and the same LOU/M Wsl rat. Albuminuria 
due to renal damage led to extremely low serum albumin levels. So ascites 
and hydrothorax are not necessarily a consequence of the observed 
cardiomyopathy, but may be due to low plasma osmotic pressure. 
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INTRODUCTION 
Doxorubicin has a well established place in the treatment of breast 
carcinoma, malignant lymphoma, acute lymphocytic and myelocytic leukemia, 
soft tissue sarcomas, and various other malignancies (1). Its clinical use 
is limited by cardiotoxicity. The incidence of cardiotoxicity sharply rises 
after a cumulative dose of 550 mg/m2 (2). 
The cardiotoxicity of doxorubicin has urged for extensive research in 
order to improve the therapeutic index of this broad-spectrum 
antineoplastic agent. To study the cardiotoxicity, animal models have been 
described for the rabbit (3, 4, 5, 6, 7), the dog (8), the golden hamster 
(9) the rat (10, 11, 12) and the mouse (13, 14, 15). Any proposal for 
increasing the therapeutic index, whether it concerns the introduction of 
analogs, the prevention of deleterious oxidative processes or avoiding peak 
levels by altering the usual schedules, compels the investigator to show 
that the antitumor activity has not been lost. Except the Moloney-sarcoma 
virus induced sarcoma (16, 17) in the rat, we are not aware of a rat model 
in which the influence of any modification on both toxicity and 
antineoplastic effect on a solid tumor in the very same animal was studied 
s imultaneously. 
We decided to study the feasibility of the LOU/M Wsl rat bearing a 
solid immunocytoraa as a model for doxorubicin-induced cardiotoxicity 
studies, allowing simultaneous studies of antitumor effects. As 
nephrotoxicity does occur in doxorubicin treated animals, special attention 
was also given to function and morphology of the kidney. 
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MATERIALS AND METHODS 
Animals 
Breeding pairs of LOU/M Wsl rats and the IgM immunocytoma of LOU/C Wsl 
origin were kindly provided by Dr.H.Bazin (Catholic University of Louvain, 
Brussels, Belgium) (18). Animals were bred at our Institute. Male rats, 
weighing 170-220 g and 12 weeks of age were used, 8 animals per group in 
tumor-bearing experiments and 4-5 in the non-tumor-bearing experiments. 
Housing conditions 
The animals were housed in pairs in wire cages. Water and commercially 
available food (Muracon, Hope Farms, Woerden, The Netherlands) were 
provided ad libitum. The concentration of Vitamin E in the food was 67.5 
mg/kg and selenium was present in trace amounts. Animal rooms were kept at 
a temperature of 22-250C and a relative humidity of 50-55%. 
Tumor model 
In the LOU/C inbred rat strain a high incidence of immunocytomas 
occurs secreting a variety of monoclonal immunoglobulins (19, 20). Because 
of poor breeding of the LOU/C rat in which the IgM tumor originally 
appeared, the histocompatible LOU/M rat was used as recipient for the IgM 
immunocytomas. Tumor cells, harvested by trypsinization (0.25% trypsin) of 
solid tumors, were stored in liquid nitrogen. The tumor cells in each 
experiment were used after one s.c. in vivo passage. The animals were 
inoculated subcutaneously on the left flank with 1 χ 10 IgM immunocytoma 
cells in 0.5 ml plain RPMI-1640 medium (Gibco, Europe B.V., Hoofddorp, The 
Netherlands). The growth of the tumor was measured twice a week with a 
vernier callipers and expressed as mean value of three perpendicular 
measurements. Most animals injected with 1 χ 10 IgM immunocytoma cells 
developed a palpable tumor after 17-21 days, which grew to a diameter of 
2-3 cm within 6-7 days. At this time the tumor has metastasized to the 
regional lymph nodes and micrometastases in the liver can be detected. 
Experimental design 
D 
Doxorubicin (Adriablastine , Farmitalla Carlo Erba Benelux, Brussels, 
Belgium) was prepared from commercially available 10 mg vials by 
reconstituting the lyophilized powder with sterile water to a concentration 
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of 2.0 mg/ml. For the lower concentrations the solution was diluted with 
physiological saline. 
Two experiments were performed. The first experiment was done with 
tumor-bearing animals as described above. Eighteen days after tumor cell 
inoculation i.v. injections were started and performed on five consecutive 
days and then weekly. In this experiment the following dosages were used: 
no treatment; 0.015 mg/kg; 0.030 mg/kg; 0.060 mg/kg; 0.125 mg/kg; 0.250 
mg/kg; 0.50 mg/kg; 1.0 mg/kg; and 2.0 mg/kg. The no-treatment group was 
injected with physiological saline (1.0 ml/kg body weight). Because the 
tumor secretes paraproteins, interference with protein metabolism and 
kidney function is to be expected. Therefore a second experiment was done 
without inoculation of tumor cells. In this experiment the same treatment 
schedule was applied and the following dosages were used: no treatment; 
0.125 mg/kg; 0.250 mg/kg; 0.5 mg/kg; 1.0 mg/kg; 2.0 mg/kg; and 4.0 mg/kg. 
The first day of injection was assigned day 0. The animals were weighed 
once weekly. Blood was obtained once weekly by orbital puncture. Sera were 
stored at -20oC, for determination of total protein, albumin, and 
creatinine values. Proteinuria was assessed twice weekly. Tumor 
measurements were also done twice weekly. For histologic examination 
animals were killed under diethylether anaesthesia. 
Histology 
Tissue of the heart, liver, spleen, kidneys, lung, and the tumor 
inoculation site was fixed in 4% buffered formaldehyde and embedded in 
glycolmethacrylate or paraffin. One um glycolmethacrylate sections were 
made of the heart and the kidney. Longitudinal sections were made of the 
heart, which included the free wall of the right ventricle, the myocardial 
septum, the free wall of the left ventricle and the atria, and longitudinal 
and transverse sections were made of the kidneys. All 1 jim 
glycolmethacrylate sections were stained with hematoxylin-eosin like 
staining, Giemsa, toluidin blue, or periodic acid silver methenamine (PASM) 
and were examined with a light microscope. The lesions in heart tissue were 
scored according to Billingham (21). In the heart the number of mast cells 
was scored semi-quantitatively. Five um paraffine sections of liver, spleen 
and tumor inoculation site were stained with hematoxylin-eosin (HE). 
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Electron microscopy 
To evaluate the light microscopy findings separately 4 control animals 
and animals treated with doxorubicin were studied after a cumulative dose 
of 12 mg/kg. At autopsy tissue of the heart was fixed by immersion in 2% 
glutaraldehyde in 0.1 M phosphate buffer. After postfixation in 1% 
Millonig's phosphate buffered OSOA and dehydration, the heart tissue was 
embedded in epon. One tim sections were stained with toluidin blue and 
studied with a light microscope. Ultrathin sections were cut with an LKB 
ultramicrotome (LKB, Bromma, Sweden), double stained with uranyl acetate 
and lead citrate and examined with a Philips EM 201 or 400 electron 
microscope. 
Biochemistry 
ρ 
Proteinuria was assessed with Albustlx (Ames, Division of Miles 
Nederland, Weesp, The Netherlands). The strongly positive samples were 
confirmed by gel electrophoresis. 
Total protein was determined according to the method described by 
Lowry in an automatic device (Cabas Bio, Roche, Basel, Switzerland) 
simultaneously with the creatinine value, which was determined with a 
picrate method. The ratio albumin:total protein was obtained by analysing 
the extinction curve after gel electrophoresis of the sera. The areas under 
the curve were measured with electronic equipment (Videoplan, Kontron GmbH, 
Munich, GFR). The samples which showed very low albumin levels were 
analysed with electro-immunodiffusion according to Laurell, using rabbit 
anti-rat albumin serum for confirmation of the results (courtesy of 
Dr.A.M.Hagenaars, Department of Immunochemistry. RIVM). 
Statistics 
Differences in group means were analysed by Student's t-test (two-
tailed) . 
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RESULTS 
Clinical observations in tumor-bearing animals. 
Antitumor effect; dose response relationship. 
At the start of administration of doxorubicin (day 18), the diameter 
of tumors was 15.8 ± 3.8 mm. As shown in text-figure 1, in the no-treatment 
group the diameter on day 28 was 37.2 ± 3.2 mm. As death was suspected 
soon, these animals were killed. The 0.015 mg/kg and 0.03 mg/kg groups 
showed no inhibition of tumorgrowth and were killed on day 28 (data not 
shown). The tumors of the 0.06 mg/kg and 0.12 mg/kg groups reached a 
diameter of 37.2 ± 2.3 mm and 36.9 ± 3.1 mm on day 32; the animals of these 
groups were killed because of the tumor size. Shortly after the start of 
therapy the tumors of the 0.25 mg/kg groups showed inhibition of growth. 
18 25 32 39 i t 53 60 67 73 doy« 
ШІІ l i l i l í 
öfter S.C inoculation al tumor cells 
I с admirastralion of drug t = 1 animal died 
K/t > killed becaute ot tumor siz« KAs = lolled becauu of ascites 
• = 2 animals (without tumor] still alive at day 175 
Text-figure 1. Effect of doxorubicin (iv administered) on growth of solid 
IgM immunocytoma in L0U/M rats. 
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However, after day 25 tumor growth was observed, and on day 32 the 
diameter of the tumor was 32.6 ± 1.7 mm. It was decided to kill these 
animals. Tumor regression was observed in the 0.5 mg/kg group. On day 39 
the nadir of tumor diameter was reached: 5 mm. After day 39 tumor growth 
resumed except in two animals, which were still alive without tumor on day 
175. Two animals died on day 53. The remaining animals were killed on day 
73. A complete regression was obtained in the 1.0 mg/kg group and no 
recurrences were observed, however the animals were killed because of 
ascites on day 70. On day 32 the animals of the 2.0 mg/kg group had a 
palpable mass of 7.6 ± 5.1 mm (data not shown). These animals were killed 
on day 35 because of ascites. 
Body weight, ascites and hydrothorax 
The no-treatment group showed a slight increase in body weight during 
the observation period. Weight loss was seen in a dose-dependent way in the 
0.5 mg/kg, 1.0 mg/kg, and 2.0 mg/kg group. The latter group showed during 
the remission-induction a loss of weight of 15%, followed by a gain which 
was related to clinically detectable ascites. For this reason the animals 
were killed. Ascites was also observed on day 52 after start of therapy in 
the 1.0 mg/kg group, for which reason they were killed. At autopsy ascites 
was found to be associated with hydrothorax. 
Clinical observations In non-tumor-bearing animals. 
Body weight, ascites and hydrothorax. 
Administration of doxorubicin above 0.5 mg/kg resulted in weight loss, 
which was dose dependent. In the 1.0 mg/kg group weight loss of 15% was 
observed on day 42. Thereafter some animals developed ascites and 
hydrothorax, which was associated with weight gain. Animals of the 2.0 
mg/kg group showed a reduction of body weight of 24% at day 7. These 
animals did not develop ascites. Ascites was neither observed in the 4.0 
mg/kg group, which was killed already before day 7 because of extreme 
emaciation. 
Histology 
Heart. All animals of each group were studied, provided that fresh 
tissues were obtained. The number of animals examined is shown in 
parentheses in Table 1. 
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Table 1. 
Semiquantitative assessment of 1 ^ ші 2-hydroxyethyl methacrylate-embedded 
sections of morphologic changes in the myocardium in LOU/M rats after 
iv administration of doxorubicin. 
Dose 
mgAg 
0 
0.5 
1.0 
2.0 
4.0 
0 
0.125 
0.250 
0.5 
1.0 
2.0 
Cumulative 
dose, mg/kg 
5.0 
11.0 
12.0 
20.0 
1.75 
3.5 
7.0 
14.0 
10.0 
Day of 
assessment 
Tumor-bearing 
85 
85 
52, 53, 80 
8 
8 
Non-tumor-bear: 
10 
14 
14 
42 
56 
14 
rats 
Lng 
n
a 
4 
4 
3 
5 
5 
rats 
7 
2 
7 
3 
6 
6 
Cardiomyopathy 
gradeb 
0 
0 
III 
I 
0 
0 
0 
0 
0 
III 
I 
a
 Number of animals assessed. 
Grading system according to Dillingham et al. (21). 
The lower dosage groups of both tumor-bearing and non-tumor-bearing 
animals showed no evidence of cardiac damage. In the 0.5 mg/kg groups no 
clear-cut morphologic changes were seen. In the 1.0 mg/kg groups however 
severe lesions were found: diffuse vacuolisation and extensive lysis of 
myofibrils (figs. 1-2) in both ventricular walls, without an area of 
predilection. They were classified as grade III cardiomyopathy. In the 2.0 
mg/kg groups only sporadic lesions were seen, which were scored as grade I 
cardiomyopathy. In the 4.0 mg/kg group of non-tumor-bearing rats, which 
64 
were killed before day 7 no cardiac lesions were observed. There were no 
differences between tumor-bearing and non-tumor-bearing animals. 
Semiquantitative evaluation of mast cell numbers did not yield a 
difference between the no-treatment groups and the doxorubicin-treated 
groups. 
Ultrastructural investigation of damaged myocardium revealed 
distension of the sarcoplasmatic reticulum and the transverse tubular 
system, dissolution of the myofibrils with loss of the characteristic 
bands. In addition, disruption of the intercellular tight junctions was 
seen, suggesting that the loss of mechanic coupling of the cells augments 
the detrimental effects of doxorubicin. The figures 3 and 4 are 
representative for the observed myocardial lesions. 
Kidney. Examination of the kidneys revealed no histologic changes In 
the no-treatment groups of both tumor-bearing and non-tumor-bearing animals 
(Figs. 5-6). Above 0.25 mg/kg lesions became evident. Marked alterations 
in the periphery of the glomeruli were seen, with synechial bands between 
the parietal and visceral leaves of Bowman's capsule, actually obliterating 
its space (Fig. 7). In the tubuli protein casts were seen (Fig. 8). The 
epithelium showed degenerative and regenerative changes with polymorphism 
of nuclei and numerous mitotic figures. In the epithelium of the proximal 
tubules fine granules were seen, which in additional histochemical staining 
showed resemblance to haemosiderin. No calcifications were seen. 
Liver and spleen. In the no-treatment group of tumor-bearing animals 
the liver was displaced by tumor cells. Microscopically the liver was only 
recognizable as such by the characteristic distribution of portal areas and 
central veins. With increasing dosages of doxorubicin less tumor cells were 
seen in the liver. In the 1.0 mg/kg and the 2.0 mg/kg groups no metastases 
in the liver were seen. Similar results were obtained with the spleen. 
Tumor inoculation site. In the 1.0 mg/kg treatment groups no viable 
tumor cells were seen in the tumor inoculation site. However a massive 
accumulation of pigment-laden macrophages were found containing brown and 
yellow granules. By additional Perl's staining the former could be 
identified as hemosiderin. In addition, the macrophages showed yellow 
autofluorescence, identifying the second pigment as ceroid. 
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LEGENDS TO THE FIGURES 
1. Cross section of myocardium of a tumor-bearing rat treated with 1 
•"Ê/kg doxorubicin, showing diffuse vacuolisation of myocardial 
fibers. 
1 лип 2-hydroxyethyl methacrylate embedded section; Giemsa 
staining; 320x. 
2. Longitudinal section of myocardial fibers of a tumor-bearing rat 
treated with 1 mg/kg doxorubicin showing lysis and vacuolisation. 
1 ym 2-hydroxyethyl methacrylate embedded section; Giemsa 
staining; 320x. 
3. Extensive vacuolization of the sarcoplasmic reticulum of a 
cardiac myofiber from a doxorubicin treated tumor-bearing rat. 
The appearance of all mitochondria is normal; 6500x. 
4. Electron micrograph of a doxorubicin treated tumor-bearing rat. 
At the left side of the intercalated disk all myofibrils are 
widely separated and disintegrated. The Z-bands are out of 
register; 9500x. 
5. Picture of renal cortex of a tumor-bearing rat of the no 
treatment group showing quite regular basement membrane of the 
glomerular tufts, intact brush border in the proximal tubules 
and regular nuclei. 
1 γα 2-hydroxyethyl methacrylate embedded section; PASM staining; 
320x. 
6. Detail of tubular structures in the renal cortex of a tumor 
bearing rat of the no treatment group showing regular nuclei and 
an intact brush border. 
1 |im 2-hydroxyethyl methacrylate embedded section; Giemsa 
staining; 320x. 
7. Renal cortex of tumor-bearing rat treated with 1 mg/kg 
doxorubicin. There is proliferation of cells of the parietal 
leave of Bowman's capsule (arrow). Bands seem to have been formed 
between the parietal and visceral leaves of Bowman's capsule. 
1 ym 2-hydroxyethyl methacrylate embedded section; PASM staining; 
320x. 
8. Detail of the renal cortex of a tumor-bearing rat of the 1 mg/kg 
group. The proximal tubuli are composed of cubic cells, which 
lost their brush border. The nuclei show a marked polymorphism. 
Note the presence of protein casts. 
1 Aim 2-hydroxy ethyl methacrylate embedded section; Giemsa 
staining; 320x. 
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Table 2. 
Serum albumin levels in LOU/M rats during administration of doxorubicin 
Doxo- Serum albumin levels8 at days after 
rubicin start of doxorubicin treatment 
dose, 
mg/kg 0 7 14 42 56 
Tumor-bearing rats 
0.5 31.6 ± 2.1 29.8 ± 1.9 31.0 ± 3.4 23.7 ± 7.1 25.4 ± 2.9 
(8) (8) (8) (5) (3) 
1.0 33.6 ± 4.1 28.9 ± 2.1 27.3 ± 2.6 6.2 ± 2.4 1.5 ± 0.5 
(8) (8) (8) (7) (8) 
2.0 24.9 ± 10.3 26.9 ± 4.4 4.0 ±1.3 
(7) (8) (8) 
Non-tumor-bearing rats 
0.5 40.0 ± 8.5 40.6 ± 1.8 32.5 ± 1.9 23.9 ± 4.5 22.4 ± 3.9 
(2) (2) (4) (4) (4) 
1.0 41.3 ± 0.5 38.1 ± 2.1 21.6 ± 2.3 9.9 ± 8.0 
(2) (3) (4) (3) 
2.0 44.0à3.6 22.6±3.0 
(5) (3) 
a
 Mean and SD of albumin levels are expressed in g/liter. 
Numbers in parentheses are numbers of observations. 
b
 Ρ < 0.05 (vs. day 0). 
c
 Ρ < 0.01 (vs. day 0). 
d
 Ρ < 0.001 (vs. day 0). 
Serum albumin concentration. On day 0 the mean serum albumin 
concentration of all animals used in the tumor-bearing experiment was 31.2 
±4.4 g/1 and in the non-tumor-bearing experiment it was 40.8 ± 4.9 g/1. 
This difference was statistically significant (p < 0.001; Student's t-test, 
two-tailed). 
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Tumor-bearing animals. Seven days after starting therapy in the no 
treatment group of tumor-bearing animals the serum albumin level decreased 
to 21.9 ± 3.1 g/1, probably due to the loss of liver parenchyma, resulting 
in impaired albumin production . With increasing doses of doxorubicin the 
decrease of the serum albumin level was less pronounced but was 
statistically significant for all lower dosage groups (data not shown). 
Table 3. 
Assessment of urinary albumin concentrations in LOU/M rats during 
iv administration of doxorubicin 
Urinary albumin concentration at days after start 
of doxorubicin treatment* Doxorubicin 
dose, mg/kg 
14 42 85 
Tumor-bearing rats 
0 
0.125 
0.250 
0.5 
1.0 
2.0 
+ 
+ 
+ 
+ 
+ 
+ 
-H-+ 
++-H 
Non-tumor-bearing rats 
0 
0.125 
0.250 
0.5 
1.0 
2.0 
4.0 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-H-
+++ 
+ 
+ 
+ 
+ 
-H-
+ 
+ 
+ 
+ 
Summary of the weekly assessments: + - trace amount, + - 0.3-1.0 g/liter, 
++ - 1.0-3.0 g/liter, +++ - 3.0-10.0 g/liter, ++++=>10.0 g/liter. 
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In the 0.5 mg/kg group which obtained a temporary tumor remission a fairly 
constant albumin concentration was seen. Serum albumin levels of rats 
treated with 1.0 and 2.0 mg/kg declined sharply to near zero levels (table 
2). These results were confirmed with the electroimraunodiffusion assay 
according to Laurell with rabbit anti-rat albumin sera. 
Non-tumor-bearing animals. From day 42 the 0.5 mg/kg group showed a 
serum albumin level, which was significantly lower than the prior treatment 
level (p < 0.05) (table 2). The 1.0 mg/kg group showed from day 14 a 
significant decrease in serum albumin level (p < 0.01) and at day 42 a 
very low serum albumin level of 9.9 ± 8.0 g/1. The 2.0 mg/kg group showed 
already on day 7 a significant decrease in albumin level (p < 0.001). 
Albuminuria 
At day 0 the albumin concentration in urine in both the tumor-bearing 
and non-tumor-bearing animals was between trace amount and 1.0 g/1 (table 
3) animals. A dose dependent increase of proteinuria was observed, 
reaching levels > 10 g/1 for the 1.0 mg/kg and 2.0 mg/kg respectively on 
day 14 and 42. In non-tumor-bearing animals this level was found in the 1.0 
mg/kg group on day 85. 
Serum creatinine levels 
Prior to the administration of doxorubicin, the serum creatinine level 
of tumor-bearing rats was higher than the serum creatinine level of non-
tumor-bearing rats (67.8 ± 5.6 vs. 51.8 ± 2.6) (Table 4). During the 
treatment of the tumor-bearing animals a gradual decrease of serum 
creatinine level was noticed already after 7 days. A dose dependent effect 
was seen on day 14 above a dose of 0.125 mg/kg body weight doxorubicin. On 
day 49 the 0.5 and 1.0 mg/kg groups had obtained a serum creatinine level 
comparable to the pretreatment level of non-tumor-bearing animals 
(respectively 50.9 ± 1.6 and 52.6 ± 10.7). At that time the remaining 
animals were free of tumor except one in the 0.5 mg/kg group. 
The non-tumor-bearing animals showed during the experiment some 
fluctuation in serum creatinine level. At the end-point of the experiment 
however, no significant change was observed. 
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Table 4. 
Serum creatinine levels in LOU/M rats during administration of doxorubicin 
Doxo­
rubicin 
dose, 
mg/kg 
0.5 
1.0 
2.0 
0 
69.7 ± 5.5 
(8) 
73.4 ± 5.2 
(8) 
67.3 ± 4.1 
(7) 
Serum creatinine levels at 
7 
62.6 ± 2.8 
(8) 
61.0 ± 3.1 
(8) 
56.4 ± 4.7 
(8) 
days after start of 
doxorubicin treatment 
14 
tumor-bearing 
70.0 ± 5.5 
(8) 
60.3 ± 3.1 
(8) 
52.0 ± 3.7 
(6) 
42 
rats 
55.8 ± 3.7 
(5) 
39.7 ± 7.2 
(6) 
-
35 
50.9 ± 1.6 
(3) 
52.6 ± 10.7 
(8) 
-
Non-tumor-bearing rats 
0.5 
1.0 
2.0 
46.6 ± 1.4 
(2) 
53.6 ± 3.2 
(2) 
50.0 ± 2.0 
(5) 
54.5 ± 1.6 
(2) 
58.3 ± 1.9 
(3) 
75.4 ± 5.8 
(3) 
51.9 ± 1.9 
(4) 
50.5 ± 4.5 
W 
63.9 ± 2.1 
W 
56.7 ± 3.9 
(3) 
58.9 ± 6.3 
(4) 
46.8 
a
 Mean and SD of creatinine levels are expressed in pmol/liter. 
Numbers in parentheses are numbers of observations. 
b
 Ρ < 0.01 (vs. day 0). 
Ρ < 0.001 (vs. day 0). 
Ρ < 0.05 (vs. day 0). 
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DISCUSSION 
This study has shown that the IgM immunocytoma in the LOU/M Wsl rat is 
susceptible for doxorubicin in a dose dependent way. The 1.0 mg/kg group 
treated with the schedule described in the section Materials and Methods, 
showed a complete regresión of tumor without recurrences. The lower dosage 
groups (0.015 mg/kg - 0.5 mg/kg doxorubicin) experienced antitumor 
activity, which was insufficient, i.e. death in these treatment groups was 
due to tumor growth. The 2.0 mg/kg dose in both tumor-bearing and non-
tumor-bearing animals, and the 4.0 mg/kg dose in non-tumor-bearing animals 
caused early death due to acute toxicity, not related to cardiomyopathy. 
The well-known pathology of anthracycline induced cardiomyopathy was 
reproduced in the 1.0 mg/kg and 2.0 mg/kg groups. When light microscopy 
findings were compared to electron microscopy observations, it is concluded 
that the 1 fun light microscopy technique was adequate for assessing 
cardiomyopathy. 
The 2.0 mg/kg group received a cumulative dose, which was 
approximately equal to the cumulative dose in the 1.0 mg/kg group (12.0 
versus 11.0 mg/kg), suggesting that development of cardiomyopathy is not 
only dose dependent but also time dependent. The 1.0 mg/kg dose represents 
a compromise dose between the dose needed for antitumor activity and a dose 
at which acute toxicity is non-lethal, permitting the anthracycline related 
cardiomyopathy coming to expression. 
Besides the cardiomyopathy, extensive renal damage could be 
demonstrated, leading to proteinuria and extreme hypoalbuminaemia in a 
dose-dependent way, both in tumor-bearing and non-tumor-bearing animals. 
The lower serum albumin levels in the tumor-bearing animals could be 
accounted for by the combination of dimimished synthesis due to metastatic 
liver disease in addition to the high protein demand of the immunocytoma. 
Furthermore urinary loss of paraproteins could have contributed to this 
effect. Extremely low serum albumin levels were observed. 
The higher serum creatinine levels in tumor-bearing animals in 
comparison to non-tumor-bearing animals may be explained by the detrimental 
effects of tumor products on creatinine clearance. The treatment with 
doxorubicin resulted in parallel with tumor load reduction in an 
improvement of serum creatinine values. The physiological meaning of the 
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minor changes observed is however doubted. In the non-tumor-bearing 
experiment no trend in serum creatinine values could be observed: the 
proteinuria evoked by doxorubicin is not accompanied by an increase of 
serum creatinine values. 
Nephropathy in the rat in relation to treatment with an anthracycline 
has been mentioned early in literature (22). Accumulation of body fluids 
has been accepted as a manifestation of chronic heart failure due to 
anthracycline induced cardiomyopathy (4, 23, 24). Also in our study 
development of ascites was observed in the 1.0 mg and 2.0 mg/kg group of 
tumor-bearing animals, which correlated with a rapid increase of body 
weight. 
However, not only heart failure, but also loss of plasma oncotic 
pressure due to hypoalbuminemia may cause accumulation of fluid in the 
body. Hypoalbuminemia has been mentioned in literature (25, 26, 27). 
Detailed studies on serum albumin levels were reported by Bristow (26) for 
the rabbit and by Bertani (25) for the rat. In neither study the near zero 
level which we observed was reported. The extremely low albumin levels 
could be the results of strain-related different sensitivity for the 
anthracycline induced effects, for the autoanalyzer method used by Bristow 
(26) and the gelelectrophoresis used by Bertani (25) gave comparable 
results. Bertani studied serum albumin levels after a single administration 
of doxorubicin 7.5 mg/kg, whereas this study describes serum albumin levels 
after repeated administration of low doses doxorubicin. The hypocalciaemia 
observed by Mettler could be related to hypoalbuminaemia (23). 
The loss of albumin and therewith the loss of plasma colloid osmotic 
pressure should have tremendous consequences for the circulation and may be 
responsible for ascites and hydrothorax. In literature on the human 
nephrotic syndrome a distinction is made between a high-renin, high-
aldosterone with vasoconstriction variant and a low-renin, low-aldosterone 
with sodium-overloading variant (28). Pilot-studies in our Institute have 
shown that after treatment with doxorubicin in vivo a decreased heart-
minute-volume could be demonstrated, whereas the same hearts showed no 
signs of cardiac failure by the method of Langendorff (unpublished data), 
suggesting that contractility is intact and vasoconstriction plays a role 
in these in vivo results. In addition to the consequences of 
hypoalbuminaemia for the circulation the role of anthracycline-induced 
vasoactive substances recently have been emphasized (26, 29). In our study 
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no influence of doxorubicin on the number of mast cells in the heart was 
observed. 
In conclusion, since the search for less cardiotoxic anthracycline 
analoga or variations in posology with retaining antitumor activity is 
still relevant for human medicine, animal models are needed for testing the 
effects of changes in treatment. Besides the Moloney Sarcoma Virus induced 
osteosarcoma we are not aware of a rat model, which allows the simultaneous 
assessment of antitumor activity and cardiotoxicity (17, 24). However, 
interpretation of data on cardiomyopathy in animal models should be 
accompanied by data on nephrotoxicity, since gross findings of ascites 
and/or hydrothorax are not only explained by heart failure but also by 
hypoalbuminemia, which is observed in anthracycline treated rats and 
rabbits. 
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Chapter б 
Time course study on doxorubicin induced nephropathy and 
cardiomyopathy in male and female LOU/M Wsl rats. 
Lack of evidence for a causal relationship. 
Accepted for publication in: JNCI. 
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SUMMARY 
In a previous study on doxorubicin induced cardiotoxicity in LOU/M Wsl 
rats severe nephropathy has been observed. Therefore, the question was 
raised whether nephropathy adds to, or even might be responsible for 
doxorubicin induced cardiomyopathy in rats. To elucidate this question we 
studied the temporal relationship between the onset of doxorubicin induced 
cardiomyopathy and nephropathy. In addition, we examined whether 
modifications of the treatment schedule could circumvent nephrotoxicity. 
Because preliminary studies had shown that female LOU/M Wsl rats developed 
less doxorubicin induced albuminuria, both male and female LOU/M Wsl rats 
were treated with doxorubicin 1 mg/kg dose i.v. on 5 consecutive days and 
then weekly. Saline treated animals served as controls. Albuminuria, serum 
albumin, and serum creatinine levels were assessed weekly. For histologic 
examination 5 male and 5 female rats were killed weekly. 
At day 14 and thereafter male doxorubicin treated rats showed 
albuminuria > 10 g/1. Albuminuria of > 10 g/1 was not avoided by 
modifications of the treatment schedule. Female rats had on day 14 an 
urinary albumin level of 1.0 - 3.0 g/1, yet reaching the > 10 g/1 level at 
day 49. In male rats serum albumin levels decreased to levels below 10 g/1 
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(ρ < 0.001 vs. day 0); in contrast female rats maintained serum albumin 
levels till day 49. Serum creatinine levels showed a tendency to rise, the 
values of male rats not being measured after day 28 due to hyperlipidemia, 
the levels of female rats increased from 37.8 ± 3.0 |imol/l to 53.7 ± 2.5 
-fimol/l on day 49 (p < 0.001). At day 10 a grade 1-1.5 cardiomyopathy 
score, assessed according to the modified Billingham scoring system, was 
found, both in males and females, gradually increasing to grade 2.5-3 
cardiomyopathy on day 49. In male LOU/M rats the nephropathy developed 
steadily from day 14 and thereafter, whereas in females the rate of 
development of kidney damage was slower and at the endpoint of the study 
the severity of kidney lesions less in comparison to males. The onset of 
cardiomyopathy and nephropathy was simultaneously. It is concluded that 
cardiomyopathy observed in LOU/M Wsl rats is a phenomenon independent of 
nephropathy. 
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INTRODUCTION 
Rats and rabbits are frequently used to study the cardiomyopathy 
induced by doxorubicin and related compounds (1, 2). In both species the 
long term toxic effects of doxorubicin consist not only of cardiomyopathy, 
but also of nephropathy (1-U). Morphologically the renal damage is 
characterized by glomerular, tubular, and interstitial pathology (2-5). 
Functionally, the nephropathy in the rat causes albuminuria and 
hypoalbuminemia finally resulting in nephrotic syndrome resulting. 
In clinical medicine doxorubicin induced nephropathy is not observed. 
One might conclude therefore, that doxorubicin cardiomyopathy and 
nephropathy are independent phenomena. Van Vleet et al., however, have 
concluded that doxorubicin induced nephropathy represents an important 
cause of death in chronically treated rabbits and detracts greatly from the 
value of the rabbit as a model for chronic cardiomyopathy studies (6). 
The IgM immunocytoma in the LOU/M Wsl rat has shown to be a tumor 
system, in which toxicity and antitumor activity of doxorubicin and platina 
compounds have been studied simultaneously (1, 2, 7), In addition, the 
entrapment of doxorubicin into negatively charged liposomes has proven to 
decrease the toxic effects of doxorubicin on kidney and myocardium, with 
preservation of the antitumor effect (1). Functional studies in our 
Institute have provided clues for the activation of compensatory mechanisms 
for the negative effects of doxorubicin induced nephrotoxic syndrome (8). 
After a cumulative dose of 7 mg/kg body weight, non pre-Instrumented 
anaesthetized LOU/M Wsl rats demonstrated on day 25 after start of 
administration of doxorubicin in vivo a higher myocardial performance when 
compared with control rats. In addition, the inotropic response towards 
dobutamine or norepinephrine as well as the vasoconstrictor response 
towards norepinephrine were profoundly impaired. However, the isolated and 
perfused rat heart showed on day 25 after the same treatment schedule with 
doxorubicin no changes in myocardial contraction under basal nor inotropic 
stimulatory conditions. 
Considering the conclusion of Van Vleet about the relationship between 
nephrotoxicity and cardiomyopathy, and the aforementioned functional data 
obtained at our Institute, we decided to investigate whether the 
nephropathy in the LOU/M Wsl rat detracts from its value as a model for 
studies on doxorubicin induced cardiomyopathy. 
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Previous studies (1, 2) in our Institute had indicated that 
doxorubicin 1 mg/kg dose on five consecutive days and thereafter weekly 
provided a balance between desired antitumor activity and acute toxicity, 
ultimately resulting in grade 3 cardiomyopathy according to the Billingham 
score (9), severe hypalbuminemia, and severe nephropathy. In kidney tissue 
after one single dose of 1 mg/kg doxorubicin at 4 h after i.v. injection a 
doxorubicin tissue level of 12.97 ± 1.00 mg/kg and at 24 h a level of 5.58 
± 1.10 mg/kg have been found (1). The administration of drug on five 
consecutive days might result in drug accumulation in the kidney. 
Therefore, the influence of modifications in the dose schedule, eventually 
resulting in a cumulative dose of 10-13 mg/kg doxorubicin on day 70 after 
start of treatment, on nephrotoxicity assessed by albuminuria, has been 
investigated. 
To elucidate the sequence of events, we have performed a time course 
study on the relationship in time between the occurrence of nephropathy and 
cardiomyopathy in the LOU M/Wsl rat. Preliminary studies had shown that 
after administration of doxorubicin male LOU M/Wsl rats developed 
albuminuria, and consequently hypalbuminemia, which were more severe and 
occurred earlier, than in female rats. Therefore, the severity of 
nephropathy and cardiomyopathy is compared weekly in both male and female 
LOU/M Wsl rats. A divergence in severity of nephropathy and cardiomyopathy 
in any sex would point at the independence of both phenomena in this animal 
system. 
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MATERIALS AND METHODS 
Animals. Breeding pairs of LOU/M Wsl were kindly provided by 
Dr.H.Bazin (Catholic University of Louvain, Brussels, Belgium). Animals 
were bred at the National Institute of Public Health and Environmental 
Hygiene. Female and male animals weighing 162 ± 12 g (n - 43) and 259 ± 21 
g (η - 43) respectively, and 12 weeks old were used. The animals were 
housed in pairs in wire cages. Water and commercially available food 
(Muracon, Hope Farms, Woerden, The Netherlands) were provided ad libitum. 
Experimental Design. Doxorubicin (Adriablastine , Roger Bellon S.A. 
Neuilly sur Seine, France) was obtained commercially. The lyophilized 
powder was reconstituted with sterile water to a concentration of 2.0 
mg/ml. The solution was further diluted to a concentration of 1.0 mg/ml 
with saline 0.9% w/v. In the part of the study, which dealt with the 
effect of different treatment schedules, only male LOU/M Wsl rats were 
used. Four groups were formed, each consisting of 6 animals. Doxorubicin 
was administered into the tail vein at a 1 mg/kg dose. Group 1 was treated 
on days 1, 2, 3, 4, 5, 12, 19, 26, 33, 40, 47, 54 and 61, obtaining a 
cumulative dose of 13 mg/kg. Group 2 was treated on days 1, 4, 11, 18, 25, 
32, 39, 46, 53, 60 and 67, cumulative dose 11 mg/kg. Group 3 was treated on 
days 1, 8, 15, 24, 31, 38, 45, 52, 59 and 66, cumulative dose 10 mg/kg. 
Group 4 was treated on days 1, 4, 15, 18, 29, 32, 43, 46, 57 and 59, 
cumulative dose 10 mg/kg. Urinary albumin concentration was assessed twice 
weekly. 
In the time course study, doxorubicin was administered i.v. in a 1 
mg/kg dose on five consecutive days and then weekly in male and female 
rats. In previous studies this regimen had shown both to have antitumor 
activity against an IgM immunocytoma and to induce damage to the structure 
of kidney and myocardium (2). This regimen did not result in weight loss 
as determined by weekly assessment. The last administration was on day 47. 
On days 0, 10, 14, 21, 28, 35, 42, 49, five rats of both sexes were killed. 
The histology of kidney and heart of doxorubicin treated animals was 
compared with that of saline treated control animals which were autopsied 
on day 49 after start of treatment. 
For light microscopic evaluation tissue of the heart and kidney was 
fixed in 4% buffered formaldehyde and embedded in 2-hydroxyethyl 
methacrylate. One -Um sections were made and stained with Giemsa. 
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Scoring system. Cardiac lesions were graded according the modified 
scoring system, proposed by Torti et al. (7) (Table 1). Kidney lesions were 
scored on a severity scale with the following gradings: no lesions (0); 
minor lesions (+); moderate lesions (++); and severe lesions (+++). The 
following items were assessed: alterations of glomerular basal membranes, 
changes in glomerular epithelial cells, the distribution of lesions through 
the glomerulus (segmental versus global), and the distribution of the 
lesions through the renal cortex (focal versus diffuse). 
TABLE 1 
Cardiomyopathy scoring system ' 
Grade Description 
0 normal cells 
1 < 5% of the cells have myofibrillar loss 
or distended cytoplasmic vacuolisation 
or both 
1.5 5-15% of the cells have myofibrillar loss 
or cytoplasmic vacuolisation, or both 
2.0 16-25% of the cells show changes as described 
above 
2.5 26-35% of the cells show changes as described 
above 
3.0 > 35% of the cells show changes as described 
above 
1) Adapted from M.E.Billingham (8) 
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For electron microscopic evaluation, 1 mm blocks of kidney tissue 
were fixed by immersion in 2% glutaraldehyde in 0.1 M cacodylate buffer. 
After postfixation in 1% cacodylate buffered OSOA and dehydration the 
kidney tissue was embedded in epon. One um sections were stained with 
toluidine blue and studied with a light microscope. Electron microscopic 
work was done on selected sections. Selection was based on severity of 
lesions observed in light microscopic survey. Ultrathin sections were cut 
with an LKB ultramicrotome (LKB, Bronuna, Sweden), double stained with 
uranyl acetate and lead citrate, and examined with a Philips EM 201 or 400 
electron microscope. 
Biochemistry. Blood was obtained weekly by orbital puncture and before 
autopsy by puncture of the aorta under ether anaesthesia. The serum 
albumin level was assessed by a brillant cresyl-purple method and serum 
creatinine levels with a picrate method in an automatic device (Cobas Bio, 
Roche, Basel, Switzerland). Urinary albumin concentrations were assessed 
ρ 
weekly by Albustics (Ames, Division of Miles Nederland, Weesp, The 
Netherlands). 
Statistics. Differences in group means were analysed by Student's t-
test (two-sided). In case of insufficient homogeneity of variances, the 
Welch correction with respect to the degrees of freedom was applied. 
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RESULTS 
Albuminuria 
In the p a r t o f the s tudy on m o d i f i c a t i o n s o f t h e t r e a t m e n t s c h e d u l e , 
animals o f group 1 reached an ur inary albumin c o n c e n t r a t i o n o f > 10 g/1 on 
day 16 a f t e r s t a r t o f t reatment ( T e x t - f i g u r e 1 ) . On day 32, a l l animals i n 
groups 1-4 had u r i n a r y albumin c o n c e n t r a t i o n s o f > 10 g / 1 . This l e v e l o f 
a lbuminuria c o r r e l a t e d w i t h a cumulat ive dose o f d o x o r u b i c i n v a r y i n g from 4 
t o 6 mg/kg. Th is l i n e o f i n v e s t i g a t i o n has n o t been c o n t i n u e d . 
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Text-figure 1: Albuminuria in Lou/M rats induced by doxorubicin in 
different treatment schedules. 
urinary albumin concentration: 1-0.3 - 1.0 g/1; 2-1.0 
3.0 g/1; 3 - 3.0 - 10.0 g/1; 4 - > 10.0 g/1. 
88 
Both female and male LOU/M Wsl rats have spontaneously albuminuria in 
the range 0.3 - 1.0 g/1 (Text-figure 2). After administration of 
doxorubicin a rapid increase in urinary albumin concentration occurred. At 
day 14 male rats reached an urinary albumin concentration of > 10 g/1. 
Female rats, however, had at day 14 an urinary albumin concentration in the 
range of 1.0 - 3.0 g/1, increasing to the range of 3.0 - 10.0 g/1 at day 28 
and thereafter. Not before day 49 female rats obtain similar urinary 
albumin concentrations as their male counterparts. 
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Text-figure 2: Time relationship between albuminuria, nephropathy, and 
cardiomyopathy in Lou/M rats during treatment with 
doxorubicin. 
\ — i.v. injection of 1 mg/kg 
urinary albumin concentration: 1 - 0.3-1.0 g/1; 2 - 1.0-3.0 
g/1; 3 - 3.0-10.0 g/1; 4 - >10.0 g/1. 
Nephropathy: 0 - no lesions; 1 - minor lesions; 2 - moderate 
lesions; 3 - severe lesions. 
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Serum albumin levels 
The serum albumin levels after prolonged doxorubicin treatment of 
LOU/M Wsl male and female rats are presented in Text-figure 3. In contrast 
to the female rats, male ones showed a rapid and strong decrease in serum 
albumin level, starting already at day 14 after the first DXR treatment 
(cumulative dose 6 mg/kg). From day 0 until day 49 the serum albumin levels 
of female LOU/M Wsl rats exhibited a slight tendency to decrease but did 
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Text-figure 3: Serum albumin levels in male and female Lou/M rats during 
i.v. treatment with doxorubicin. 
ι - i.v. injection of 1 mg/kg. 
* : ρ < 0.05; ** : ρ < 0.01; *** : ρ < 0.001 compared to day 
0 ;»p < 0.05 compared to female rats on the same day 
»» ρ < 0.01; ***. ρ < 0.001. 
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not differ significantly, except for levels on days 21 and 49. At the last 
day the difference reached the significance level of ρ < 0.001, the 
cumulative dose being 11 mg/kg. Meanwhile male LOU/M Wsl rats had serum 
albumin levels of almost zero, reflecting the severe albuminuria in these 
animals. 
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Serum creatinine levels 
Serum creatinine levels of female LOU/M Wsl rats had increased 
significantly from a value of 37.8 ± 3.0 umol/l at day 0 to 50.6 ± 2.1 
umol/l at day 35 and thereafter (Text-figure 4). Male LOU/M Wsl rats 
showed after day 14 a gradual increase of serum creatinine level which 
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Text-figure 4: Serum creatinine level in male and female Lou/M rats during 
i.v. treatment with doxorubicin, t - i.v. injection of 1 
mg/kg. ** ρ < 0.01; *** : ρ < 0.001 compared to 
day 0; *»:p < 0.01 compared to female rats on the same 
day. 
however did not reach statistical significance. After day 28 serum 
creatinine levels in the males could not be measured any longer, due to 
turbidity of the hyperlipidemic serum. 
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Cardiomyopathy 
Low cardiomyopathy scores were observed for male and female LOU/M Wsl 
rats till day 35. On the average the score of male rats was during this 
period of observation slightly ahead of the score of female ones. On day 
35 and thereafter a sharp increase in cardiomyopathy score for both sexes 
was seen. No essential difference between male and female LOU/M Wsl rats 
could be ascertained after day 35. The cardiac lesions consisted of 
vacuollsatlon and loss of myofibrils. The lesions were in accordance with 
those described by us previously (1, 2). In control animals no 
cardlomyopathlc changes were observed. A compilation of data is presented 
in Table 2. The mean cardiomyopathy score is shown in Text-figure 2. 
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TABLE 2 
Cardiomyopathy score In male and female Lou/M Wsl rats by time and 
cumulative dose doxorubicin 
Day Cumulative 
dose mg/kg 
1.5 
grade 
2.5 ,2) 
male 
0 
10 
14 
21 
28 
35 
42 
49 
49 
female 
0 
10 
14 
21 
28 
35 
42 
49 
49 
0 
5 
6 
7 
8 
9 
10 
11 
0 
0 
5 
6 
7 
8 
9 
10 
11 
0 
5 
4 
5 
5 
5 
4 
4 
2 
1) scoring system adapted from M.E.Billingham (8) 
2) η - number of animals 
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Nephropathy 
At light microscopic examination the early stage of doxorubicin 
induced nephropathy was characterized by thickening of the epithelial 
lining of the parietal leave of Bowman's capsule. Subsequently delicate 
adhesions between the parietal and visceral leave were noticed, simulating 
epithelial blebs. Continuation of the administration of doxorubicin 
resulted in progressive destruction of glomerular architecture. The end 
stage of doxorubicin induced glomerulopathy was characterized by shrinkage 
of the glomerular structure, with complete absence of glomerular tufts, 
where in only a few nuclei were seen. During the development of the 
eventual glomerulopathy no cellular infiltrate occurred. No predilection 
for any region of the renal cortex could be revealed. In the capillaries no 
thrombi were seen. Crescent formation was absent. Examples of various 
degrees of severity of glomerulopathy are shown in Figs. 1-5. 
Very soon after the start of administration of doxorubicin protein 
casts appeared. The diameter of granules in cells of the proximal tubuli 
increased during the early stage of kidney damage. Later on, the brush 
border disappeared, and simultaneously the granules were no longer 
detectable. Eventually, atrophy of tubuli occurred. No conspicuous lesions 
in the interstitium were noticed. 
In male controls, both at day 0 and day 49, minimal glomerular 
abnormalities were present, which were absent in female controls. In male 
LOU/M Wsl rats the nephropathy continued to develop steadily and sharply, 
whereas in female rats the increase of nephropathlc lesions was less 
pronounced and the severity of nephropathy at the end of the experiment 
stood behind that of males. A compilation of data is presented in table 3. 
The mean nephropathy score is shown in Text-figure 2. 
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TABLE 3 
Nephropathy score, assessed by glomerular changes, in male and female 
Lou/M Wsl rats by time and cumulative dose doxorubicin 
Day Cumulative Scores 
dose mg/kg 
0 + ++ +++ η ' 
1 3 4 
4 1 5 
4 1 5 
1 3 4 
4 1 5 
3 2 5 
1 4 5 
4 4 
2 
4 4 
4 4 
4 1 5 
3 2 5 
4 1 5 
2 2 1 5 
5 5 
1 4 5 
1 1 2 
male 
0 
10 
14 
21 
28 
35 
42 
49 
49 
female 
0 
10 
14 
21 
28 
35 
42 
49 
49 
0 
5 
6 
7 
8 
9 
10 
11 
0 
0 
5 
6 
7 
8 
9 
10 
11 
0 
1) η - number of animals 
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Ultrastructural studies were done on kidneys of doxorubicin treated rats 
and controls, both males and females on day 35. In control animals no 
abnormalities were observed. Major lesions were found in the glomerular 
epithelium of doxorubicin treated animals. A striking change was the 
remarkable disappearance of all foot processes of podocytes in such a way 
that nearly the whole basal lamina was covered with a continuous layer of 
flattened visceral epithelial cells (Figs. 6, 7). In addition the visceral 
cells and, the parietal cells to a lesser extent, showed a large number of 
cytoplasmic vacuoles. The small and medium sized vacuoles appeared to be 
dilated rough endoplasmic reticulum (RER), but the large vacuoles were 
surrounded by a smooth membrane (Figs. 8, 9). An increased number of villi 
were present on the surface of the visceral epithelial cells and numerous 
microfibrils were present in their cytoplasm (Fig. 10). Finally the 
glomerular basement membrane was focally thickened and sometimes 
raultilayered. Occasionally large areas were completely occupied by tortuous 
and thickened layers of basement membranes. In the cytoplasm of the 
visceral epithelial cells some cross-striated fibrils were observed, 
running parallelly and next to the glomerular basement membrane. 
In female rats the lesions were less pronounced. No ultrastructural 
differences were observed in proximal tubuli between doxorubicin treated 
rats and control rats, both male and female rats. 
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1. This section shows subtle strings between the parietal and 
visceral leave of Bowman's capsule (arrow). In addition few 
swollen nuclei of the epithelium of the parietal leave 
(arrowhead). This lesion was scored grade +. 
1 firn 2-hydroxyethyl methacrylate embedded section. Giemsa χ 320. 
2. This section shows a row of swollen epithelial nuclei of the 
parietal leave of Bowman's capsule (arrow). This lesion was scored 
grade +. 
1 *im 2-hydroxyethyl methacrylate embedded section. Giemsa χ 320. 
3. A grade ++ glomerular lesion on the right next to a normal 
glomerulus demonstrating the focal character of glomerulopathy in 
part of the material. 
1 іш -2hydroxyethyl methacrylate embedded section. Giemsa χ 320. 
4. The basal membrane of the parietal leave of Bowman's capsule is 
thickened (arrow). Fseudovacuoles have been formed (asterisk). 
This glomerulus is only partly affected, and presents an example 
of segmental glomerulopathy. This lesion was scored as grade ++. 
1 ^ш 2-hydroxyethyl methacrylate embedded section. Giemsa χ 320. 
5. Pronounced thickening of the basal membrane has taken place. The 
glomerular structure is severely damaged. Note the mitotic figure 
(arrow). Protein cast are present in tubuli. This lesion was 
scored grade +++. 
1 Jam 2-hydroxyethyl methacrylate embedded section. Giemsa χ 320. 
6. Detail of control glomerulus showing some podocytes with their 
distinct foot processes (arrow), attached to the basal lamina, χ 
4950. 
7. Detail of glomerulus of doxorubicin treated rat. The basal lamina 
is covered by a nearly continuous layer of epithelial cell 
processes (arrow). Some vacuoles are present in the epithelial 
cells (asterisk), χ 7650. 
Fig. 8. Detail of glomerular podocyte of doxorubicin treated rat with 
dilated cisterns of rough endoplasmic reticulum, χ 13.800. 
Fig. 9. Large vacuoles, surrounded by a smooth membrane, are present in a 
glomerular podocyte of a doxorubicin treated rat. χ 9500. 
Fig. 10. Numerous villi are covering the surface of the visceral epithelial 
cells of a doxorubicin treated rat. χ 6500. 
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DISCUSSION 
In male and female LOU/M Usi rats spontaneous albuminuria at the 0.3 -
1.0 g/liter level is present. After administration of doxorubicin 
albuminuria increases. Albuminuria has been shown to be dose dependent (1, 
2). In this study male rats show at day 14 urinary albumin concentrations 
above 10 g/liter, while female rats reach this level more gradually yet at 
day 49. The urinary albumin scoring system is logarithmical by nature. The 
urinary albumin losses in male rats should therefore be considered 
considerable. As a consequence, the serum albumin levels in male rats 
decrease sharply. In contrast, the female rats are able to maintain their 
serum albumin level until day 42. Modification of the doxorubicin 
administration schedule did not prevent severe albuminuria. This indicates 
that variation of time intervals between subsequent doxorubicin 
administrations do not prevent doxorubicin induced toxicity. Albuminuria 
grade 4 is consistently present after day 30, the cumulative doxorubicin 
dose varying between 4 mg/kg and 8 mg/kg. These data suggest that time is 
an important factor in the expression of nephropathy. 
In contrast to the major disturbances in renal handling of albumin, 
particularly in male rats, serum creatinine levels are relatively 
unaffected. Although in both sexes a gradual increase of serum creatinine 
levels is observed, the physiological meaning is not known. Based on the 
serum creatinine levels, the decrease of glomerular filtration rate is 
estimated to be 30% maximally. Although body weight did not change during 
the experiment (data not shown), in fact there may have been a significant 
loss of muscular mass, replaced by edema. In that case, serum creatinine 
levels have been flattered. Giroux et al. (10) found after a cumulative 
dose of 7 mg/kg free doxorubicin an increase in serum creatinine level of 
0.92 ± 0.40 mg/dl to 1.40 ± 0.32 mg/ml, i.e. a decrease of creatinine 
clearance of 35% in their heminephrectomized rats. In our study, prolonged 
measurement of serum creatinine levels was impossible, due to turbidity of 
serum. The turbidity was ascribed to hyperlipidemia. Bizzi et al. (11) 
found 14-21 days after a single dose of doxorubicin (7.5 mg/kg i.v.) 
hyperlipidemia in male CD-COBS rats. Because hyperlipidemia completes the 
criteria required in nephrotic syndrome, the doxorubicin induced 
nephrotoxicity can be described as nephrotic syndrome. 
The nephropathy induced by doxorubicin in the LOU/M Wsl rat as seen by 
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light microscopy resembles the nephropathy described by Sternberg (4) for 
daunorubicin, Bertani et al. (5), and Weening et al. (12) for doxorubicin 
in their rat models. The lesions in our model are also in agreement with 
those described by Fajardo et al. (3) in the rabbit. 
The doxorubicin induced ultrastructural effects, as seen in this 
study, were identical with those in the rat reported by Bertani et al. (5). 
They supposed that the morphological changes and the proteinuria are the 
consequence of the loss of negative charge of the sialoproteins in the 
glomerular barrier by doxorubicin. Changing the electrolytic barrier of the 
glomerulus resulted in an enhanced filtration of albumin. In vivo 
perfusion experiments in the rat with polykatlons supported their 
hypothesis as the same morphological changes occurred, while perfusion with 
neutral macromolecules or polyanionic proteins induced no alterations (13). 
The small and medium sized vacuoles clearly originated from dilated 
RER. It is well known that dilation of RER is accompanied by degranulation. 
Sternberg (4) described dilation of RER cisterns after daunomycin 
administration, while Fajardo et al. (3) too noticed a widespread dilation 
of RER after doxorubicin administration in the rabbit. Seiler et al. (13) 
hypothetlzed that retraction of foot processes also could result in a 
formation of urinary pockets between epithelial cell bodies and deformed 
foot processes. 
In both sexes a steady increase in cardiomyopathy has been observed. 
No clear differences between male and female rats have been observed. 
The heavy doxorubicin induced albuminuria in male LOU/M Wsl rats, 
which exceeds an urinary albumin concentration of 10 g/1 and more on day 14 
and thereafter, is at light microscopic examination associated with 
glomerular and tubular changes. The extent and severity of nephropathy 
increases steadily in time. Urinary albumin concentrations in female LOU/M 
Wsl rats are less than in males during the experiment until day 49. In 
parallel with this result, the findings at light microscopic examination of 
the kidney are less severe and the rate of increase is less steep In 
comparison with males. From a collaborative study by Julicher et al. 
(submitted for publication), it appeared that our findings on nephropathy 
parallelled biochemical data concerning parameters of free radical stress. 
In their study more loss of enzymatic activity in the kidney of male LOU/M 
rats was found as compared to females, after 52 days of treatment with 
doxorubicin on five consecutive days and then weekly. In heart tissue no 
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clues for damage of lipids or enzymes was found both in male and female 
LOU/M rats, whereas our study clearly describes histological damage in rats 
of both sexes. Julicher et al. conclude that peroxidation of lipids is not 
decisive in the development of cardiomyopathy. 
Anthracycline induced nephropathy has been described relatively early 
in literature (4). In clinical practice no clues are present for 
doxorubicin induced nephropathy. Therefore, it is feasible that during the 
seventies no attention has been paid to the susceptibility of rats and 
rabbits for anthracycline induced nephropathy, and its possible 
interference with cardiac performance. 
The onset of cardiomyopathy and nephropathy is simultaneous in both 
sexes. The severity of cardiomyopathy in male and female LOU/M Wsl rats is 
about the same in contrast to clear difference in nephrotoxicity. 
Moreover, the onset of independent cardiomyopathy and nephropathy is 
simultaneous In both sexes. In addition, the severity of cardiomyopathy in 
male and female LOU/M Wsl rats is about the same in contrast to clear 
difference in nephropathy. Therefore, it is concluded that cardiomyopathy 
observed in LOU/M Wsl rats is a phenomenon independent of nephropathy. 
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ABSTRACT 
LOU M/Wsl rats inoculated s.c. with 10 IgM immunocytoma cells have a 
palpable tumor at day 17. Doxorubicin (DXR) has been entrapped in 
negatively charged liposomes (lip" DXR) composed of egg-phosphatidylcholine 
(PC), cholesterol (chol) and phosphatidylserine (PS) and in positively 
charged liposomes (lip DXR) composed of PC, chol and stearylamine (SA). 
DXR, lip" DXR and lip+ DXR were administered i.V. (0, 0.25, 0.5, 1.0 and 
2.0 mg/kg) at day 17 for 5 consecutive days and then weekly. Control 
animals showed progressive tumor growth leading to death 27 days after 
inoculation. Antitumor activity for all three preparations was dose 
dependent. DXR and lip" DXR showed the same antitumor activity, lip DXR 
had less antitumor activity. The overall survival of tumor bearing animals 
treated with 2.0 mg/kg lip" DXR was significantly prolonged (p < 0.05) in 
comparison to the animals treated with 2.0 mg/kg free DXR. Grade III 
cardiomyopathy was observed 47 days after treatment with free DXR; 
treatment with lip" DXR resulted in grade I cardiomyopathy. In animals 
treated with 1.0 mg/kg and 2.0 mg/kg free DXR urinary albumin 
concentrations of 10 g/1 were observed. Treatment with 1.0 mg/kg lip" DXR 
and 1.0 mg/kg lip DXR resulted in urinary albumin concentration of < 3.0 
g/1 and < 1.0 g/1, respectively. Free DXR 1.0 mg/kg resulted in a decline 
of serum albumin concentration from 27.8 ± 3.2 g/1 to 9.6 ± 4.2 g/1. No 
such decline was observed after treatment with lip" DXR and lip DXR. 
107 
Treatment with 1.0 mg/kg dose of free DXR resulted in severe glomerular and 
tubular lesions which were not found after treatment with 1.0 mg/kg lip" 
DXR and 1.0 mg/kg lip+ DXR. Administration of lip" DXR resulted in lower 
DXR levels in cardiac and renal tissue compared to administration of free 
DXR. After administration of lip+ DXR very low tissue and tumor DXR levels 
were found. 
In conclusion, treatment with lip" DXR or lip DXR resulted in a 
prolonged survival, less albuminuria, and higher serum albumin levels. Also 
less lesions in heart and kidney were found, correlating with lower DXR 
levels in these organs. Only lip" DXR had the same antitumor effect as free 
DXR. 
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INTRODUCTION 
Doxorubicin is a very important antitumor agent with a wide spectrum 
of activity (4). Its clinical application is hampered by chronic 
cardiotoxicity, which incidence rises steeply above a cumulative dose of 
550 mg/m (18) . Therefore current recommendations suggest that total 
о 
cumulative doses should not increase above 550 mg/m . The chronic 
cardiotoxicity is morphologically characterized by myofibrillar loss, 
vacuolisation of the sarcoplasmic reticulum and ultrastructurally by 
swelling of mitochondria, disruption of mitochondrial crystae, and loss of 
tight junctions. In rabbits and rats, morphological and functional changes 
of the kidney have also been described (2, 7, 12, 31, 32). 
To increase the therapeutic index of doxorubicin, several lines of 
research have been developed. The concomitant administration of anti­
oxidants, e.g. OC-tocopherol, has been studied in animal systems (6, 23, 30, 
33) and has been clinically evaluated (20). The development and clinical 
testing of analogs is a major area of research (8). Further alteration of 
pharmacokinetic behavior designed to avoid high plasma DXR peak levels, has 
been subject of research. Decrease of the incidence of cardiotoxicity has 
been described after small weekly doses (34), and favorable results in 
clinical trials have been reported on continuous infusion (19, 21). 
To improve the therapeutic index of DXR, entrapment of the drug into 
liposomes has recently drawn considerable attention. Liposomes are 
preferentially cleared from the plasma by tissues with a sinusoidal 
capillary system and by the mononuclear phagocyte system. After i.v. 
injection a high level of DXR, which was entrapped in liposomes, was found 
in the plasma, liver, spleen and lung compared to administration of free 
drug (15, 24, 27). This offers the opportunity to deliver relatively large 
amounts of cytostatic drugs to liver and lung, organs which are common 
sites of metastatic disease. Therefore, the usefulness of DXR entrapped in 
liposomes has been studied (13, 14, 15, 24, 27, 28, 29). 
Thusfar, several mouse models have been reported in which the use of 
DXR entrapped in liposomes has shown similar or enhanced antitumor activity 
and reduced cardiomyopathy compared to free DXR (13, 14, 15, 24, 28, 29). 
Rahman found less antitumor activity for DXR entrapped in negatively 
charged liposomes (28). In all reports reduced cardiomyopathy was 
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accompanied by lower concentration of DXR in cardiac tissue. Moreover 
Forssen en Takes (14) showed that there was no correlation between the 
absolute amount of drug delivered into the tumor and the level of antitumor 
activity. 
Comparing the effectiveness of several kinds of liposomes, one finds 
conflicting results. Rahman et al. (28, 29) have reported on cardiac 
protection and identical antitumor activity obtained by administration of 
positively charged liposomes, whereas negatively charged liposomes did not 
preserve myofibrillar integrity and showed less antitumor activity against 
s.c. implants of Lewis lung carcinoma. In contrast, Olson et al. (24) and 
Forssen and Tökes (13, 14) reported on reduction of DXR induced 
cardiotoxicity and increased antileukemic activity with DXR entrapped into 
negatively charged liposomes. No general rule can yet be given for the type 
of liposome to be preferred. 
The entrapment of DXR in liposomes might influence the kinetics of DXR 
in such a manner that not only toxicity, but also antitumor activity is 
diminished. Therefore it is extremely important to study at the same time 
antitumor activity and cardiomyopathy of liposome entrapped DXR in tumor 
bearing animals. We report here on the application of DXR entrapped in 
liposomes, with high stability and prolonged shelf life, which were well 
defined regarding charge, size, and polydispersity index, in the IgM 
immunocytoma bearing Lou/M Wsl rat (11, 32). In this study liposome 
entrapped DXR is compared to free drug in a multiple dosage regimen with 
respect to antitumor activity, survival, cardiotoxicity, nephrotoxicity, 
and tissue distribution of DXR. 
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MATERIALS AND METHODS 
Animals. Breeding pairs of LOU/M Wsl rats and the transplantable IgM 
immunocytoma of LOU/C Wsl origin were kindly provided by Dr.H.Bazin 
(Catholic University of Louvain, Belgium) (1). Animals were bred at the 
National Institute of Public Health and Environmental Hygiene, Bilthoven, 
The Netherlands. Male rats, weighing 170-220 g and 12 weeks of age were 
used. Animals were maintained according to accredited procedures in our 
facility and enjoyed uniformly good health at the initiation of the 
studies. 
Tumor model. LOU M/Wsl rats were inoculated subcutaneously on the left 
flank with 1 χ 10 IgM immunocytoma cells in 0.5 ml plain RPMI-1640 medium 
(Gibco, Europe B.V. Hoofddorp, The Netherlands). Details on the tumor model 
are described elsewhere (32). The growth of the tumor was measured twice a 
week with vernier callipers and expressed as mean value of three 
perpendicular measurements. Most animals inoculated with 1 χ 10 cells 
developed a palpable tumor after 17-21 days, which grew to a diameter of 
25-35 mm within 6-7 days. At this time the tumor has metastasized to the 
regional lymph nodes and micrometastases in the liver can be detected (11). 
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Drug preparation. Doxorubicin (Adriablastine ) was purchased from 
Laboratoire Roger Bellon S.A., Neuilly sur Seine, France. For experiments 
with the free drug, the lyophyllzed powder of 10 mg/vials was reconstituted 
and diluted with sterile saline 0.9% w/v. 
Preparation of liposomes. The chemical composition of the liposomal 
bilayers was adapted from Rahman et al. (28, 29). Positively charged 
liposomes consisted of egg yolk alpha-L-phosphatidylcholine (PC), type V-E 
(Sigma Chemicals, St.Louis, Miss., USA), cholesterol (chol) (Sigma 
Chemicals) and stearylamine (SA) (ICN Pharmaceuticals, Cleveland, Ohio, 
USA) in the molecular ratio 10 : 4 : 3. For negatively charged liposomes 
the molecular ratio of PC : chol: bovine brain phosphatidylserine (PS) 
(Sigma Chemicals, St.Louis, Miss., USA) of 10 : 4 : 1 was used. DXR from 
commercially available vials, which contain lactose, was mixed with PC, 
cholesterol and SA or PS in 5 ml of a chloroform/methanol mixture 1 : 1 
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(reagent grade). The dispersion of positively charged liposomes were 
sonicated (Bransonic B12, probe type sonicator, Stanford, Conn., USA) in 
consecutive 2 minute bursts separated by an one minute rest interval. The 
multilamellar structures were removed by ultracentrifugation at 10 g for 
one hour (4 ο0). Negatively charged liposomes were extruded sequentially 
through Nucleopore membrane filters with pore sizes of 600 and 200 run. 
Separation of free from liposome bound DXR was achieved by dialysis. The 
dispersions with the positively or negatively charged liposomes contained 
0.2 mg/ml and 0.5 mg/ral DXR, respectively. Freshly prepared liposomal 
preparations were administered. Details of the preparation procedure are 
reported elsewhere (9, 10). Particle size was determined by dynamic light 
scattering (Nanosizer, Coulter Electronics, Ltd., Lutton, U.K.). One day 
after ultracentrifugation positively charged liposomes with DXR had a mean 
diameter of 0.10 •μιη. During dialysis this mean diameter and, in particular, 
the polydispersity of the liposomes tended to increase. After dialysis a 
mean diameter of 0.12 (um was found. The reproducibility of the mean 
liposome diameter of the extruded negatively charged liposomes was 0.27 ± 
0.01 ym (n - 11). The polydispersity index was low. These data did not 
change during dialysis or storage. 
The zeta-potential of the liposomes was determined by 
microelectrophoresis (Rank Brothers Mark II, Bottisham, U.K.). For lip 
DXR a zeta-potential of 22 mV was calculated. The zeta-potential for lip" 
DXR was found to be -9 mV. 
Experimental design. Fourteen groups consisting of 6 animals each were 
formed at random. Seventeen days after tumor cell inoculation treatment was 
started. The tumor diameter was 18.1 ± 3.1 mm. For data relating to 
administration of drug the first day of i.v. injection was assigned day 0. 
I.v. injections were performed on five consecutive days and then weekly. 
The following dosages were used: saline 0.9%, 0.25, 0.5, 1.0, and 2.0 mg/kg 
free DXR; empty lip", 0.25, 0.5, 1.0 and 2.0 mg/kg DXR in Up"; empty lip+, 
0.25, 0.5 and 1.0 mg/kg DXR in lip+. The 2.0 mg/kg lip+ DXR dose was not 
applied. Due to the relatively very low DXR content in positively charged 
liposomes, we were not able to produce a sufficient amount of lip DXR to 
perform this part of the experiment. 
The animals were weighed once weekly. Tumor measurements were done 
twice weekly. Albuminuria was assessed weekly. Blood was obtained weekly 
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by orbital puncture. Sera were stored at -20° С for determination of 
albumin and creatinine levels. 
To compare the severity of the cardiomyopathy and nephropathy induced 
by free or liposome entrapped DXR, all animals of the same dosage groups 
were killed as soon as one animal of the free DXR group (1.0 or 2.0 mg/kg) 
developed clinically conspicious ascites or became moribund. In this way 
fresh tissues of animals treated with an equal accumulative dose were 
obtained for histological examination. 
Survival study. For studies on survival 30 animals were randomly 
distributed in three groups. All animals were inoculated with 1 χ 10 IgM 
immunocytoma cells on the left flank. On day 21 the tumor had reached a 
diameter of 20 mm; on this day treatment was started. In the first group, 
which was treated with saline 0.9% w/v, one animal died intercurrently 
before treatment was initiated. The second group received 2.0 mg/kg DXR, 
the third group 2.0 mg/kg lip" DXR. Intravenous injections of saline or 
drug were given on five consecutive days and then weekly. Mortality was 
scored. No additional data were collected in this part of the study. 
Histopathology. Tissue of the heart and kidneys was fixed in 4% buffered 
formaldehyde and embedded in 2-hydroxyethyl methacrylate. One Лип sections 
were stained with Giemsa and examined with a light microscope. The lesions 
in heart tissue were scored according to Billingham (3). 
Biochemistry. Albuminuria was assessed with Albustix (Ames, Division of 
Miles Nederland, Weesp, The Netherlands). The serum total protein, serum 
albumin, and serum creatinine levels were determined in an automatic device 
(Cobas Bio, Roche, Basel, Switzerland). 
Tissue distribution studies 
For determination of DXR tissue distribution three groups of 12 tumor 
bearing rats each were formed. Four and 24 h after administration of 1 
mg/kg DXR, 1 mg/kg lip" DXR, and 1 mg/kg lip+ DXR respectively, 6 animals 
were killed. Plasma, heart, kidney, lung, liver, spleen, quadriceps 
musculature and tumor were collected and stored at -20° С until analysis. 
Plasma was analysed according to the method described previously (5). 
For determination of DXR in organs, tissues were freeze-dried as whole 
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organs during 24 hours and then finely powdered and homogenized in a 
mortar. Powdered samples of 100 mg, accurately weighed, were transferred 
into a 15 ml polypropylene tube. Then, 100 lil of a daunorubicin (Specia, 
Paris, France) internal standard solution (4 mg per liter distilled water) 
and 500 «Л silver nitrate solution (330 g per liter distilled water) were 
added. The mixture was vortexed for 10 seconds and after addition of 500 ul 
sodium chloride solution (2 M in distilled water) vortexed again during 10 
seconds. After adjusting the pH - 9.0 by means of 3.0 ml of the borax 
buffer solution pH - 9.0 (53.5 g of borax per liter distilled water 
containing approximately 70 ml IM HCl) 3.0 ml of a chloroform-1-heptanol 
mixture (1 : 1) was added. The mixture was shaken for 10 minutes and then 
centrifuged for 10 minutes at 2000 g. The aqueous upper layer was removed 
and the organic layer was transferred into a 5 ml polypropylene tube 
containing 300 |il 0.1 M phosphoric acid. After 1 min. vortexing and 10 min. 
centrifugation at 2000 g, 100 |il of the phosphoric acid phase was injected 
into the chromatographic system. The system consisted of a model 6000, a 
solvent delivery system and a WISP 710 A automatic injection system (both 
from Waters Assoc, Milford, MA., USA). The detector was a Perkin Elmer 
(Norwalk USA) Model 204 fluorescence detector equipped with a 25-fil flow 
cell (Hellma GmbH, type 176.70, Mtlllheim Baden GFR). Fluorimetrie detection 
was performed at excitation wavelength 470 run and emission wavelength 562 
nm. A LiChrosorb RP-8 (Hibar 125-4, Merck, Darmstadt, FGR) reversed phase 
column (125 mm χ 4 mm I.D., particle size 5 4im) was used in combination 
with a pellicular reversed phase filled guard column (75 mm χ 2.1 mm I.D., 
Chrompack, Middelburg, The Netherlands). The mobile phase consisted of 
acetonitrile-distilled water - 0.1 M phosphoric acid (42 : 55 : 3) 
containing 10 yg desipramine-HCl per ml and was filtered through a 0.22 lim 
filter under reduced pressure before use. The flow rate was 2 ml/min. All 
chromatographic analyses were performed at room temperature. The reagents 
were of analytical grade and used without further purification. 
Calibration curves were constructed by adding known amounts of standards to 
pooled, freeze-dried, finely powdered, homogenized, non treated rat 
tissues. Tissue DXR content was calculated from the ratio between the 
areas of the fluorescence of the internal standard and the tissue extracted 
DXR. During each run of the automatic injector, four standards were 
injected too. Simultaneously with each series of rat tissues the standards 
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were subjected to the extraction procedure. 
With this method linear results were obtained to at least 20 mg per kg 
freeze-dried tissue. The detection limit was 0.1 mg/kg. Calibration curves 
for the analysis of spiked, pooled, freeze-dried non-treated rat tissues 
were linear over the range 0.2 mg/kg to 20 mg/kg and pass through the 
origin (r - + 0.999). Tissue concentrations exceeding the studied upper 
limit were re-analysed by weighing an appropriate amount of freeze-dried 
tissue powder. 
Statistics. Differences in group means were analysed by Student's t-test 
(two-sided). In case of insufficient homogeneity of variances, the Welch 
correction with respect to the degrees of freedom was applied. 
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RESULTS 
Antitumor activity (Chart 1). Administration of saline 0.9% w/v, empty 
negatively or positively charged liposomes did not inhibit tumor growth. 
Doses of 0.25 mg/kg free DXR, lip" DXR, and lip+ DXR retarded tumor growth. 
At days 7, 11 and 14 the differences between 0.25 mg/kg free DXR versus 
lip" DXR and lip+ DXR were statistically significant (p < 0.05). 0.5 mg/kg 
Free DXR and lip" DXR resulted temporarily in regression of tumor, however 
the antitumor activity of free DXR was superior at day 18 (p < 0.05), 21 
and 25 (p < 0.01) and 28 (p < 0.05). Lip+ DXR 0.5 mg/kg had only a 
retarding effect on tumor growth. Tumor regression was seen in all animals 
treated with 1.0 mg/kg, but was least pronounced in animals treated with 
lip DXR. No significant differences in the mean tumor diameter were found 
between free DXR and lip" DXR . Regrowth of tumor was seen in all groups. 
The 2.0 mg/kg free DXR and 2.0 mg/kg lip' DXR groups showed a nearly 
complete regression of tumor, but because of emaciation of the free DXR 
group, both groups were killed on day 14. 
Body welftht. Treatment with 1.0 mg/kg dose of free DXR resulted in a 
decrease of body weight of 8.1% within 10 days after the start of drug 
administration. Body weight diminished 4.1% in 1.0 mg/kg lip" DXR group and 
3.2% in 1.0 mg/kg lip + DXR treated groups. The difference between DXR and 
lip" DXR was statistically not significant. In the lip" DXR group, 
however, twenty-eight days after the start of therapy, a rise of bodyweight 
was observed to a level 10% above the weight on the first day of treatment. 
This rise could not be correlated with the development of ascites. 
A very steep decline (-40%) of body weight was observed in the 2.0 
mg/kg free DXR group. In contrast, the 2.0 rag/kg lip" DXR group lost 10% of 
their bodyweight during the first 14 days of treatment (p < 0.001). The 
same pattern was seen in the survival experiment. 
Ascites. Ascites was observed when serum albumin levels had dropped below 
10.0 g/1. After a cumulative dose of 12.0 mg/kg DXR it was observed on day 
14 in the 2.0 mg/kg free DXR group. The first sign of ascites in the 1.0 
mg/kg group was observed on day 47, after a total cumulative dose of 10 
mg/kg free DXR. In contrast, none of the groups treated with lip" DXR and 
lip DXR developed ascites. 
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Chart 1. Effect of liposome-entrapped DXR on growth of solid IgM 
immunocytoma in LOU/M Wsl rats. A:i.v. injection; A, DXR in 
saline; B, DXR in lip+ DXR; C, DXR in lip" DXR; 0 diameter, mean 
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Table 1. 
Effect of free doxorubicin (DXR) and doxorubicin entrapped in negatively 
(lip" DXR) or positively (lip+ DXR) charged liposomes on cardiomyopathy of 
tumor bearing animals. 
doxorubicin 
dosage mg/kg 
cardiomyopathy number of day of 
score animals assessment 
0.25 
1.0 
2.0 
saline 0.9% 
empty lip" 
empty lip 
DXR 
ИР" 
lip+ 
DXR 
lip" 
lip+ 
DXR 
Up" 
lip+ 
DXR 
DXR 
DXR 
DXR 
DXR 
DXR 
DXR 
DXR 
0 
0 
0 
0 
0 
0 
III 
I 
I 
I 
I 
ND 
3 
3 
2 
5 
5 
2 
4 
4 
2 
5 
4 
10 
17 
47 
14 
Grading system according to Billingham (3) 
Day of assessment day 33 
c
 ND - not done 
Histology 
Heart. As shown in Table 1, the saline, empty negatively charged or 
positively charged liposome treated animals showed no histologic 
abnormalities of the heart. Neither were myocardial lesions seen in the 
0.25 mg/kg groups, which survived 17 days after the start of drug 
administration. Animals of all 0.5 mg/kg dose groups died because of tumor 
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growth without obtaining fresh tissue samples for histologic examination. 
47 Days after the initiation of therapy the 1.0 mg/kg free DXR treated 
group had developed vacuolisation and lysis of myofibrils diffusely 
throughout the myocardium, to grade III cardiomyopathy according to 
Billingham (3). Animals treated with 1.0 mg/kg lip" DXR, which were killed 
at the same day showed only sporadic myocardial lesions, to grade I 
myocardiopathy. Assessment of cardiomyopathy in the animals treated with 
1.0 mg/kg dose of lip DXR took place on day 33, because tumor growth 
necessitated killing of the animals. In this group grade I cardiomyopathy 
was found. Both 2.0 mg/kg free DXR and lip" DXR treatment groups showed on 
the 14th day after the start of the therapy of the drug sporadic myocardial 
lesions, scored as grade I cardiomyopathy. 
Kidney. The control and 0.25 mg/kg dose groups showed no glomerular and 
tubular abnormalities. Treatment with 1.0 mg/kg free DXR resulted in 
extensive glomerular le'sions as described previously (32). Synechial 
connections between the parietal and visceral leaves of Bowman's capsule, 
suggesting the existence of large vacuoles, were striking. Some glomeruli 
were infiltrated with many mononuclear cells, other ones were rather 
depleted of cells. The brush border of the proximal tubules was lost. The 
proximal, distal and collecting tubules showed anisocytosis and 
polymorphism of their nuclei. Mitotic figures were seen. Numerous protein 
casts were present in the collecting tubules. In contrast, the glomeruli 
of 1.0 mg/kg lip" DXR treated animals showed only sporadic septate 
connections between the parietal and visceral leaves of Bowman's capsule. 
No lesions were noted in the 1.0 mg/kg lip treated animals. 
The short living 2.0 mg/kg free DXR treated group showed slight to 
moderate glomerular lesions. The 2.0 mg/kg lip" DXR treated animals showed 
only sporadic glomerular lesions. 
Albuminuria. The urinary albumin concentration at the start of therapy was 
in the 0.1 - 0.3 g/1 range. Treatment with free DXR (1.0 and 2.0 mg/kg) 
resulted in a rapid increase of urinary albumin to a concentration above 10 
g/1. Treatment with lip" DXR resulted in urinary albumin concentration to 
levels < 3.0 g/1, whereas treatment with lip DXR 1.0 mg/kg limited urinary 
albumin concentration to < 1.0 g/1. A compilation of data is given in 
Table 2. 
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Table 2. Effect of DXR, lip" DXR and lip+ DXR on urinary albumin 
concentration of tumor bearing animals. 
urinary albumin concentration 
doxorubicin days after starting free lip lip 
dosage mg/kg treatment DXR DXR DXR 
0 
14 
21 
28 
0 
14 
21 
28 
47 
10 
< 0.3 
< 3.0 
< 3.0 
< 3.0 
< 0.3 
< 3.0 
>10.0 
>10.0 
>10.0 
>10.0 
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
0.3 
3.0 
1.0 
3.0 
0.3 
1.0 
1.0 
3.0 
3.0 
3.0 
< 0.3 
< 3.0 
< 0.3 
< 1.0 
< 1.0 
< 1.0 
-
ND 
Urinary albumin concentrations were assessed by Albustic and 
expressed in g/1. ND - not done. Number of observations; 6-3 animals. 
Serum albumin levels (Table 3). In the 1.0 mg/kg free DXR group a gradual 
decrease of serum albumin level was observed, whereas in the 2.0 mg/kg free 
DXR group a very steep decline was seen. Treatment with lip" DXR 1.0 mg/kg 
and 2.0 mg/kg preserved serum albumin levels. In the forementioned dosage 
groups treatment had resulted in relevant tumor regression. 
Animals, which received no DXR, showed a decline in serum albumin 
level. The same was observed in all 0.5 mg/kg dosage groups, and in the 
lip DXR 1.0 mg/kg group. All these groups are characterized by the 
presence of a huge tumor mass, which might interfere with protein 
metabolism. 
Serum creatinine levels. Treatment with free DXR, lip" DXR or lip+ DXR did 
not result in significant change in serum creatinine levels compared to the 
serum levels before treatment. Initial and end point values are shown in 
Table 4. 
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Table 3 
Effect of doxorubicin and doxorubicin entrapped in negatively (lip DXR) or positively (lip DXR) charged 
liposomes on serum albumin levels of tumor-bearing animals. 
doxorubicin 
dosage mg 
0 
0.5 
1.0 
2.0 
/kg 
days after 
starting 
treatment 
0 
7 
10 
0 
17 
25 
33 
40 
0 
17 
25 
33 
40 
47 
0 
7 
10 
free 
29.9 
21.0 
19.5 
29.4 
31.7 
32.3 
22.4 
17.5 
27.8 
24.1 
20.1 
12.4 
9.6 
28.8 
24.5 
8.7 
± 
± 
+ 
+ 
+ 
+ 
+ 
± 
+ 
+ 
+ 
+ 
+ 
± 
± 
DXR 
3.2b 
2.1 
1.9 
1.1 
1.5 
2.3 
0.7 
3.2 
3.1 
6.9 
5.3 
4.2 
1.4 
2.1 
4.0 
» 
(2) 
(2) 
(4) 
Ρ 
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
value 
0.001 
0.05 
0.05 
0.001 
0.001 
NS 
0.05 
0.001 
0.001 
0.01 
0.001 
Serum a! 
lip" 
28.9 
20.9 
20.8 
29.4 
30.2 
26.5 
20.5 
26.8 
30.1 
31.3 
28.5 
26.8 
26.5 
27.7 
27.7 
28.9 
Lbumin 
DXR 
+ 
± 
+ 
± 
± 
± 
± 
+ 
+ 
+ 
+ 
+ 
+ 
± 
± 
± 
2.3 
1.5 
2.2 
1.1 
2.0 
1.3 
0.7 
2.9 
0.7 
1.5 
4.0 
4.5 
5.6 
1.6 
1.5 
1.9 
level 
(5) 
(5) 
(5) 
(5) 
(2) 
(5) 
(4) 
(5) 
(5) 
Ρ 
< 
< 
< 
< 
< 
< 
value 
0.001 
0.001 
NSC 
0.01 . 
0.01d 
0.05, 
0.05d 
NS 
NS 
lip' 
28.0 
21.6 
20.7 
28.3 
19.4 
28.9 
28.9 
24.4 
17.5 
4-
DXR 
± 
+ 
± 
+ 
+ 
± 
± 
± 
± 
ND 
1.8 
1 .2 
0.6 
3.1 
3.9 
1.5 
2.6 
3.6 
4.2 
(3) 
(4) 
(3) 
Ρ 
< 
< 
< 
< 
< 
value 
0.001 
0.001 
0.05 
NS 
0.05 j 
0.05d 
, According to Student's t-test, 2-tailed, compared to Day 0 
Mean ± S.D. serum albumin in g/liter. 
NS, not significant compared to Day 0; ND, not done. 
After Welch correction. 
Table 4 
Effect of doxorubicin and doxorubicin entrapped in negatively (lip DXR) or positively (lip DXR) charged 
liposomes on serum creatinine level of tumor-bearing animals. 
doxorubic 
dosage mg 
0.5 
1 .0 
2.0 
in 
;/kg 
days after 
starting 
treatment 
0 
17 
33 
40 
0 
33 
47 
0 
17 
free 
60.0 ± 
52.2 ± 
72.0 ± 
61.0 ± 
54.3 ± 
41 .6 ± 
50.0 + 
56.5 ± 
126.6 ± 
: DXR 
9.8Ъ 
2.1 
15.2 
1.4 
4.3 
5.8 
10.2 
6.7 
73.1 
(2) 
(5) 
(4) 
(5) 
ρ value' 
NS C 
NS 
NS 
NS 
NSd 
Serum creatinine leve 
' lip" 
56.4 
47.2 
50.5 
49.0 
50.3 
52.8 
55.5 
49.4 
" DXR 
± 10.4 
± 5.5 
± 10.6 
ND 
± 4.4 
± 5.1 
± 5.4 
± 10.5 
± 1.5 
(5) 
(5) 
(2) 
(4) 
(5) 
Ρ 
1 
value 
NS 
NS 
NS 
NS 
lip' 
48.5 
63.2 
53.5 
57.3 
f DXR 
± 5. 
± 11. 
ND 
ND 
± 10, 
± 5. 
ND 
ND 
ND 
.3 
.9 
.2 
.1 
(4) 
(3) 
ρ value 
< 0.05 
NS 
According to Student's t-test, 2-tailed, compared to Day 0. 
Mean ± S.D. of serum creatinine levels are expressed in umol/liter. 
NS, not significant (compared to Day 0); ND, not done. 
After Welch correction. 
Survival experiment. Since in the above described study the animals of 
corresponding groups were killed at the same time to obtain fresh tissues 
for histologic examination, a separate experiment was done to assess the 
survival time in the 2.0 mg/kg group. The saline treated animals showed a 
median survival time of 8 days (range 5-11) after start of therapy. The 2.0 
mg/kg DXR treated animals survived for 23 days (range 11-33 days) after 
initiation of therapy. The 2.0 mg/kg lip" DXR treated group survived 
considerably longer: median 40 days (range 17-65 days) (Chart 2). In both 
the 2.0 mg/kg free DXR and lip* DXR treated group complete regression of 
tumor without recurrence occurred (Chart 3). Ascites was observed on day 
22 (4 out of 5 animals) in the free DXR group. The animals treated with 
lip" DXR had developed ascites 12 days later. 
Serum and tissue doxorubicin content (Table 5) 
The administration of 1.0 mg/kg lip" DXR resulted 4 hours after i.v. 
injection in a plasma DXR level, which was significantly lower than the 
plasma DXR level after administration of free DXR. However, administration 
of lip DXR, resulted in a very high plasma DXR level. Twentyfour hours 
after i.V. administration of free DXR the plasma DXR level was still 
slightly higher, compared to the plasma level after administration of lip" 
DXR. No doxorubicinol could be detected in any plasma sample. 
Both in cardiac tissue and in the kidney DXR levels at 4 hr after i.v. 
administration of lip' DXR and lip+ DXR were lower than after i.v. 
administration of free DXR. Twentyfour hours after administration the same 
pattern persisted. 
DXR entrapped in negatively charged liposomes preferentially 
accumulated in liver and spleen, where at 4 and 24 h after i.v. 
administration very high tissue concentrations were found. Administration 
of DXR in positively charged liposomes resulted in tissue DXR levels in 
liver and spleen which were lower than after i.v. administration of free 
DXR at 4 h. Twentyfour hours after administration of lip+ DXR no 
significant difference was observed. 
In tumor tissue the highest DXR tissue levels were found after 
administration of free DXR. Administration of lip" DXR resulted in lower 
tumor tissue levels, statistically significant (p < 0.05) at 4 h but not at 
24 h. DXR levels in tumor tissue were higher 24 h after i.v. administration 
of lip" DXR compared to the 4h levels. Very low DXR levels in tumor tissue 
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Table 5 
Plasma and tissue concentration of DXR 4 hours and 24 hours after one i.v. injection of free, lip DXR and 
lip DXR (1 mg/kg) in IgM immunocytoma bearing rats. 
A hours 
Plasma 
Heart 
Kidney 
Muscle 
Lung 
Liver 
Spleen 
Tumor 
24 hours 
Plasma 
Heart 
Kidney 
Muscle 
Lung 
Liver 
Spleen 
Tumor 
Free DXR 
5.68 
6.72 
12.97 
2.18 
6.50 
3.76 
4.53 
2.12 
2.84 
3.28 
5.58 
2.29 
5.35 
1.13 
4.02 
2.81 
± 
± 
± 
+ 
± 
± 
± 
± 
+ 
+ 
+ 
± 
± 
± 
+ 
± 
0.56 
0.67C 
1.00 
0.28 
0.84 
0.56 
0.88 
0.65 
0.57 
0.86 
1.10 
0.37 
0.78 
0.10 
0.57 
1.08 
1 
(5) 
(4) 
(4) 
(4) 
Ρ 
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
. a 
value 
0.001 
0.001 
0.001 
0.001 
0.001 
0.001 
0.001 
0.05 
0.05 , 
0.01 d 
0.001 
0.001 
0.001 
0.001, 
0.05 ° 
NS d 
Hl 
2.04 
2.53 
4.41 
0.96 
3.16 
18.3 
54.6 
1 .40 
2.03 
0.66 
1.76 
1.27 
2.82 
3.98 
30.2 
2.04 
D 
± 
± 
± 
+ 
± 
± 
± 
± 
± 
+ 
± 
+ 
+ 
+ 
+ 
+ 
DXR levels 
DXR 
0.50 
0.43 
0.67 
0.42 
0.67 
2.5 
12.0 
0.34 
0.39 
0.37 
0.28 
0.25 
0.53 
0.98 
10.0 
0.33 
(5) 
(5) 
(5) 
(4) 
ρ value 
< 0.001 
< 0.001 
< 0.001, 
< 0.05 d 
< 0.01 d 
< 0.001 
< 0.001 
< 0.001 
NS 
< 0.001 
< 0.001 
< 0.001 
< 0.001, 
< 0.05 d 
< 0.001 
lip 
35.0 
0.74 
1.26 
0.29 
1.28 
1.44 
2.63 
0.32 
0.44 
0.58 
0.24 
0.99 
1.06 
5.06 
0.48 
*" DXR 
± 4.06 
± 0.26 
+ 0.51 
± 0.08 
+ 0.15 
± 0.36 
± 0.93 
± 0.08 
NDe 
± 0.25 
± 0.04 
± 0.05 
± 0.17 
± 0.42 . 
+ 1.89 (5) 
± 0.17 
Ρ 
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
value 
0.001 
0.001 
0.001 
0.001 
0.001 
0.001 
0.01 , 
0.01 d 
0.01 
0.001 
0.001 
0.001 
NS 
NS 
0.01 
Free DXR 
5.68 
6.72 
13.0 
2.18 
6.50 
3.76 
4.53 
2.12 
2.84 
3.28 
5.53 
2.29 
5.35 
1 .13 
4.02 
2.81 
+ 
+ 
+ 
+ 
± 
+ 
+ 
+ 
+ 
± 
+ 
+ 
+ 
+ 
+ 
± 
0.56 
0.67 
1.0 
0.28 
0.84 
0.56 
0.88 
0.65 
0.57 
0.86 
1.10 
0.37 
0.78 
0.10 
0.57 
1.08 
(5) 
(4) 
, Comparing adjacent figures. 
Mean ± S.D. of serum DXR concentration expressed in yg/liter. 
, Mean ± S.D. of tissue DXR concentration expressed in mg/kg freeze-dried tissue. 
After Welch correction 
NS, not significant; ND, not done. 
were seen after i.v. administration of lip DXR. 
With exception of the spleen, doxorubicinol was not detectable in any 
tissue. Spleen levels of doxorubicinol approximated the detection limit 
and could not be quantitated accurately. 
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DISCUSSION 
Our study showed antitumor activity for DXR entrapped in positively 
and negatively charged liposomes. However, the antitumor activity of DXR 
in negatively charged liposomes equalled the activity of free DXR, whereas 
the antitumor activity of DXR in positively charged liposomes at the three 
dosage levels investigated lagged behind the activity of free DXR. No 
antitumor activity by empty liposomes was seen. Simultaneous 
administration of negatively charged liposomes and non-entrapped DXR 
resulted in the same antitumor activity and survival as free DXR, 
underscoring the necessity of the entrapment of the cytostatic drug (data 
not shown). In comparison to free DXR, administration of lip" DXR resulted 
in diminished toxicity: both heart and kidney structure were largely 
preserved. The free DXR related depletion of serum albumin did not occur. 
The decrease in body weight related to free DXR treatment was not 
significantly diminished by lip" DXR. Delivery of DXR entrapped in 
negatively charged liposomes resulted in a prolonged survival time, and a 
higher cumulative dose of DXR, compared to administration of free drug. 
The administration of DXR entrapped in negatively charged liposomes 
resulted in plasma DXR levels and tissue DXR distribution, which differed 
from the distribution obtained after i.v. administration of free DXR. 
Plasma, heart and kidney contained less DXR at 4 as well as at 24 hours 
after i.v. administration of lip" DXR compared to i.v. administration of 
free DXR. This result parallels the finding of less signs of toxicity in 
heart and kidney on microscopical examination. In addition to the different 
DXR distribution, the favorable effects on myocardium and kidney structures 
might be explained by less direct exposition of this tissue to the drug 
entrapped in liposomes. In tumor tissue, 4 h after administration of lip" 
DXR the DXR concentration is lower than after administration of free DXR. 
At 24 hours, however, there is no difference anjrmore. This might explain 
the fact that no difference in antitumor activity is observed. 
The administration of lip DXR resulted in a quite different pattern 
of DXR concentrations. A relatively high DXR level was found at 4 h in 
plasma. The analytical method does not discern between liposome entrapped 
DXR, protein-bound DXR, and free DXR, so nothing can be said about the 
clearance of positively charged liposomes laden with DXR. The very low 
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tissue levels, even in liver and spleen, indicate a low availability of DXR 
after entrapment in the positively charged liposomes. The lesser antitumor 
activity is readibly explained by the very low DXR concentration in tumor. 
Our results with negatively charged liposomes are in agreement with those 
of Forssen and Tò'kes (13, 14), Gabizon (15) and Olson et al. (24). However, 
both at 4 h and 24 h the plasma DXR level after administration of lip" DXR 
was lower than after administration of free DXR in our experiment, whereas 
the forementioned investigators found the contrary. 
Rahman et al. (28) reported on the absence of cardioprotective 
properties, higher concentration χ time DXR value and less antitumor 
activity for DXR entrapped in negatively charged liposomes (PC : Choi : PS 
- 50.6 : 20.7 : 5.03). However, entrapment of DXR in positively charged 
liposomes (PC : Choi : SA - 50.6 : 20.7 : 14.8) resulted in lower cardiac 
peak DXR concentration and lower cardiac DXR concentration χ time value 
resulting in preservation of myocardial structure and in the same antitumor 
activity compared to free DXR. It may be that the different behavior is 
related to the species studied, or is related to differences in vesicle 
structure. Rahman (28) does not define the physical properties of his 
dispersions. 
To obtain reproducible results it is of utmost importance to use 
well-defined liposomes, which can be made in a reproducible manner. 
Therefore we carefully checked particle size, charge, and physical and 
chemical stability of DXR containing vesicles (9, 10). 
The relative cholesterol content influences the stability of a 
liposome (16, 25, 26). Despite the relatively low cholesterol content of 
our negatively charged liposomes, the stability has been satisfactory i.e. 
the leakage factor was low (10-15% after 60 days) and the shelf-life 
permitted the efficient production of larger quantities. 
There may be three explanations for the observed reduced cardiomyopathy 
after administration of liposomes: 
1. DXR entrapped in negatively charged liposomes is preferentially 
accumulated in the mononuclear phagocyte system. These cells might release 
DXR slowly into the plasma, accounting for prolonged and low plasma DXR 
levels, thus avoiding peak levels, which might initiate organ damage. 
2. Liposomes might protect tissues susceptible to toxic effects of DXR by 
retaining DXR within their membranes during the distribution phase. 
3. As a consequence of the preservation of renal integrity, serum albumin 
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levels do not decrease. This might indirectly have a favourable effect on 
myocardial function and structure, because hypoalbuminemia may have 
consequences for the circulation (32). 
The mechanism of antitumor activity is unclear. Forssen and Tokes 
measured DXR concentrations in solid tumors, as we did (14). They found 
equal DXR levels in Sarcoma 180 after free DXR and DXR in the entrapped 
form. In Lewis Lung Carcinoma, however, lower levels of DXR were found 
after administration of the entrapped form, while antitumor activity was 
enhanced. It was concluded that a correlation between antitumor activity 
and tumor DXR level lacks. These data are giving rise to speculations 
about the mechanism of antitumor activity (14). Of interest are the in 
vitro studies of Haskill (17) and Martin et al. (22), about the transfer of 
DXR by macrophages to tumor cells. If this transfer takes also place in 
vivo, entrapment of DXR in liposomes might enhance the tumoricidal activity 
of macrophages. Functional studies of macrophages after in vivo and in 
vitro administration of liposome entrapped DXR are underway in our 
laboratory. 
In conclusion, this study describes the use of DXR entrapped in 
liposomes in an IgM immunocytoraa bearing rat. DXR entrapped in positively 
charged liposomes had less antitumor activity in comparison to free DXR and 
lip" DXR. As the negatively charged liposomes used in this study have a 
prolonged shelf-life of at least 60 days and a reduced cardlotoxlcity and 
nephrotoxicity with preserved antitumor activity, studies on the 
suitability of these liposomes in clinical trials might be indicated. 
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Chapter 8 
The effect of entrapment of doxorubicin in negatively charged liposomes 
on hematoloRical parameters in the male Lou/M Wsl rat 
Q.G.C.M.van Hoesel, P.A.J.Speth, P.A.Steerenberg, G.J.A.Geleijnse, 
D.J.Th.Wagener 
SUMMARY 
Doxorubicin (DXR) and doxorubicin entrapped in negatively charged 
liposomes (lip" DXR) which had shown to have beneficial effects on 
cardiomyopathy and nephropathy with preservation of antitumor activity in 
previous studies, have been i.v. administered to 12 week old male LOU/M Wsl 
rats in 1 mg/kg, and 2 mg/kg dose on 5 consecutive days. Saline, and empty 
liposomes have been administered as controls. Blood for hematological 
parameters and determination of cellular doxorubicin concentrations has 
been obtained by exsanguination at days 6, 9, 11, 13, 20, 34 and 48 in the 
1 mg/kg experiment and on days 3, 6, 8, 10, 13 and 15 in the 2 mg/kg 
experiment. 
White blood cell counts were depressed from day 3 to day 13, without 
significant differences between the free or liposome entrapped doxorubicin 
treated groups. Thrombocyte counts were depressed from day 6 to day 13. The 
depression was dose dependent. No difference between free DXR and lip" DXR 
treated groups was observed. 
In the 1 rag/kg experiment no change in hemoglobin level was observed, 
in contrast to the 2 mg/kg experiment. No differences between the free or 
liposome entrapped doxorubicin treated groups were observed. 
Flowcytometry has shown that after cessation of treatment cellular 
doxorubicin concentration in bone marrow cells steadily increased in the 2 
mg/kg experiment, the fluorescence counts being higher in the liposome 
entrapped doxorubicin group, than in the free doxorubicin group. Despite 
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increasing doxorubicin concentrations bone marrow recovery set in. 
In conclusion, the entrapment of doxorubicin in negatively charged 
liposomes had no benificial effects on doxorubicin induced suppression of 
bone marrow activity. 
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INTRODUCTION 
Myelosuppression is the dose limiting toxicity for doxorubicin in 
every day practice (Bonadonna, 1970). On a long term, doxorubicin induced 
cardiomyopathy occurs. The incidence of cardiomyopathy rises steeply above 
2 
a cumulative dose of 550 mg/m (Lefrak, 1973). Prior radiation therapy and 
hypertension have been identified as risk factors (Minow 1977, Von Hoff 
1979). 
The encapsulation of doxorubicin in liposomes has been found to 
protect the animal in experimental systems against cardiac damage (Forssen 
1981, 1983, Olson 1982, Rahman 1980, 1982, 1985, Van Hoesel 1984a). 
Besides cardiomyopathy, doxorubicin induces nephropathy, eventually 
resulting in a nephrotic syndrome, in rabbit and rat (Bristow 1981, Bertani 
1982). Treatment with doxorubicin entrapped in liposomes reduces 
nephropathy and preserves serum albumin levels (Van Hoesel 1984a). 
The administration of doxorubicin encapsulated in liposomes resulted 
in lower tissue doxorubicin concentration 4 and 24 h after administration 
except in liver and spleen as compared to administration of free 
doxorubicin (Van Hoesel 1984a). 
In continuation of our previous studies we decided to investigate 
whether treatment with doxorubicin entrapped in negatively charged 
liposomes compared to treatment with free doxorubicin, has beneficial 
effects on white blood cell counts, differential counts, thrombocyte 
counts, hemoglobin levels, erythrocyte counts, reticulocyte counts, and 
bone marrow differential counts. In addition, doxorubicin levels in 
relevant cell populations in peripheral blood and bone marrow were assessed 
with laser flow cytometric techniques in order to correlate the findings 
with doxorubicin concentrations. 
The study was performed with negatively charged liposomes and with 
dosage levels which have been shown in previous studies to result in 
adequate antitumor activity against the IgM immunocytoma in the LOU/M Wsl 
rat (Van Hoesel 1984; Van Hoesel 1984a). 
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MATERIALS AND METHODS 
Animals. Breeding pairs of LOU/M Wsl rats were kindly provided by 
Dr.H.Bazin (Catholic University of Louvain, Brussels, Belgium). Animals 
were bred at the National Institute of Public Health and Environmental 
Hygiene. Male animals, weighing approximately 220 g and 12 weeks old, were 
used. The animals were housed in pairs in wire cages. Water and 
commercially available food (Muracon, Hope Farms, Woerden, The Netherlands) 
were provided ad libitum. 
ρ 
Drug preparation. Doxorubicin (Adriablastine , Roger Bellon S.A., 
Neuilly sur Seine, France) was obtained commercially. The lyophilized 
powder was reconstituted with sterile water to a concentration of 2.0 
mg/ml. Negatively charged liposomes (egg-phosphatidylcholine: cholesterol: 
phosphahidylserine - 10:4:1) and doxorubicin entrapped in those liposomes 
were prepared according the procedure, described elsewhere (Van Hoesel 
1984a). 
Dosage schedule. The experiments were performed at two dosage levels: 
doxorubicin 1 mg/kg and 2 mg/kg. Injections were given on five consecutive 
days into the tail vein. 
In the 1 mg/kg experiment the following groups have been investigated: 
the administration of saline 0.9% w/v; doxorubicin 1 mg/kg entrapped in 
negatively charged liposomes (lip'DXR); and free doxorubicin 1 mg/kg (free 
DXR). On days 6, 9, 11, 13, 20, 34 and 48 after the start of treatment 
five animals of each group were killed. 
In the 2 mg/kg experiment the following groups have been investigated: 
saline 0.9% w/v; empty negatively charged liposomes; doxorubicin 2 mg/kg 
entrapped in negatively charged liposomes; and 2 mg/kg free doxorubicin. On 
days 3, 6, 8, 10, 13 and 15 after the start of treatment four animals of 
each group were killed. 
Section. During ethyl ether anaesthesia peripheral blood was obtained 
by orbital puncture and subsequently the animals were killed by 
exsanguination. Part of the blood was collected in EDTA-coated vials for 
determination of hemoglobin content, blood cell counts and peripheral 
smear. Another part of the blood was collected in freshly prepared ACD 
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buffer (sodium citrate 3.22 g/1; Nal^PC^ 2H20 3.40 g/l; NajHPO 
g/l; NaCl 4.96 g/l; glucose 4.02 g/l; citric acid 1.17 g/l) and kept at 0oC 
for laser flow cytometric analysis. Bone marrow was obtained by flushing 
both femora and collected in freshly prepared ACD buffer and stored at 0oC 
until laser flow cytometric analysis. Part of the bone marrow was prepared 
for differential counts. 
Hematological parameters. Hemoglobin, mean corpuscular volume (MCV), 
erythrocyte count, and leukocyte count were measured with a Coulter Counter 
Model S5 (Coulter Electronics, Harperden, Herts, U.K.) after predilution in 
Isoton II (Coulter Electronics) 1:449,4. Thrombocyte counts were determined 
in a counting chamber after dilution in Trivinsol (RIVM) 1:200. 
Reticulocyte counts were determined on peripheral smears stained with fresh 
methylene blue counting 2000 erythrocytes. Differential counts of 
peripheral blood and bone marrow were made on smears stained in May 
Griinwald Giemsa. In peripheral smears 200 white cells were counted; in bone 
marrow smears 400 white cells on 3 slides, scoring the cells of the red 
series in the meanwhile. 
Laser Flowcytometrie (FCM) studies. With three parameter laser 
flowcytometry cellular DXR concentrations have been determined in 
hematopoietic and peripheral blood cells and their subpopulations on a 
System 50H Cytofluorography (Ortho Diagnostic Systems Inc. Westwood, MA, 
U.S.A.) equipped with a 5W argon laser (164-05, Spectra Physics, Mountain 
view, CA, USA) running at 488 ran, 0.5 W. DXR-fluorescence was measured 
with a barrier filter OG 550 (Melles Griot Optical Industries, Costa Mesa, 
CA, USA). Data on forward light scatter, perpendicular light scatter and 
fluorescence per cell were measured in area mode, stored in list mode, and 
analysed on a PDP 11/34 computer (Digital Electronic Company, Maynard, MA, 
USA). Mean cellular DXR concentrations are expressed in arbitrary 
fluorescence units/cell (FU/cell) after correction for endogenous 
fluorescence. HPLC analysis has been performed in order to correlate the 
arbitrary fluorescence unit with cellular drug concentration. As before, 
HPLC analysis has been shown to correlate well with the FCM determination 
of the cellular DXR concentration (Speth 1985). The materials and methods 
applied for FCM and PHLC have been described In detail in the latter study. 
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RESULTS 
Hematologic parameters 
Leukocyte counts are depicted in Chart 1. The control values of the 1 
mg/kg and the 2 mg/kg experiments, which were not performed synchronously 
differ significantly from each other (p < 0.01). In addition, in the 1 
mg/kg experiment the leukocyte counts in control animals drop spontaneously 
after day 20 (p < 0.05). 
Compared to their own controls, the leukocyte counts are depressed in 
both experiments from the first day of measurement (i.e. day 6 and 3 for 1 
and 2 mg/kg experiment respectively) until day 13. The administration of 
empty negatively charged liposomes had no effect on leukocyte counts. 
At both dosage levels white blood cell counts recover simultaneously 
in the free DXR and lip'DXR treated groups. 
The differential counts on peripheral smears showed that both the 
lymphoid and myeloid series were depressed (data not shown). In the 2 mg/kg 
experiment a drop of peripheral lymphocyte count in both treatment groups 
is already noticed on day 3, whereas the absolute number of granulocytes 
does not differ from control values on that day. 
In bone marrow smears of the 2 mg/kg experiment the ratio between 
young myeloid cells and the total myeloid population equals on day 3 the 
ratio found in bone marrow smears of control animals (Chart 2). After day 3 
the ratio declines with equal speed in both lip"DXR and free DXR treated 
groups. After day 8 the prevalence of young myeloid cells in the bone 
marrow rapidly increases. 
Compared to control values the thrombocyte counts in both treatment 
groups show a slight drop in the 1 mg/kg experiment (Chart 3). After day 13 
recovery begins. The 1 mg/kg free DXR treated animals show on days 20 and 
34 an overshoot in thrombocyte counts. In the 2 mg/kg experiment a 
biologically relevant decrease of thrombocyte counts in both lip"DXR and 
free DXR treated groups is observed after day 6. The recovery of 
thrombocyte counts starts after day 13. Complete recovery has not yet been 
reached at the end of the experimental period. 
In the 1 mg/kg experiment no change in hemoglobin levels is observed 
(Chart 4). In the 2 mg/kg experiment, however, the hemoglobin levels in 
both free DXR and lip"DXR treated groups decline after day 10. The findings 
for erythrocyte counts are the same as for hemoglobin levels (Chart 5). At 
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day 48 in the 1 mg/kg experiment the erythrocyte count in lip'DXR treated 
rats differed from the erythrocyte count of free DXR treated animals at the 
ρ < 0.001 level, whereas the differences from control value were at the ρ < 
0.01 and ρ < 0.001 level respectively. In the 2 mg/kg experiment at day 15 
the erythrocyte count of lip'DXR treated animals differed at ρ < 0.05 level 
from control value. The drop in hemoglobin level and erythrocyte count of 
free DXR and lip'DXR treated animals is preceded by a total depression of 
reticulocytes in both treatment groups (Chart 6). 
The MCV values remain constant during both experiments (data not 
shown). 
Laser flow cytometric data 
In peripheral white blood cells the fluorimetrie determined cellular 
DXR concentration in both treatment groups at both dosage levels scarcely 
supercedes the endogenous fluorescence of controls during and after the 
treatment period (Chart 7). 
In bone marrow at the 1 mg/kg dose level the fluorescence levels at 
day 6 are clearly higher than control values, whereas higher fluorescence 
levels are found in the group treated with lip'DXR (Chart 8). At day 9 for 
both free doxorubicin and liposomal entrapped doxorubicin cellular DXR 
concentration levels return to zero (fluorescence levels of controls). At 
the 2 mg/kg dose level a small further increase in cellular DXR 
concentration was observed in both treatment groups even after cessation of 
treatment. The highest levels are reached at day 8-10. The administration 
of lip' DXR resulted in the highest levels. After day 10 a rapid decline 
is noticed resulting in fluorescence levels in the range of control values 
at day 15. The DXR related fluorescence is particularly found in myeloid 
cells (data not shown). 
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DISCUSSION 
There are considerable differences in leukocyte control values In the 
two experiments. In addition, the leukocyte counts of the control groups at 
days 34 and 48 in the 1 mg/kg experiment show a statistical significant 
decrease. The differential counts demonstrate that the differences found in 
control values are mainly due to variations in lymphocyte counts, which 
cannot be explained (data not shown). For the reader it is important to 
know that the relative lymphocyte counts in rats are in the 75-90% range. 
The differential bone marrow counts of the 2 mg/kg experiment are 
available. Except on day 6 in the free DXR treated group the contribution 
of the lymphocytic population to hematopoietic bone marrow cells is 
increased during bone marrow suppression. The observations with regard to 
peripheral lymphocytic counts, made in this study, cannot be explained, nor 
is the biological implication clear. 
Entrapment of doxorubicin in negatively charged liposomes, did not 
result in a clear advantage compared to administration of free doxorubicin 
with regard to the degree of leukocytópenla nor the duration of it. Rahman 
et al. (1985) reported a smaller drop of the white blood cell count which 
occurred later than after administration of free drug after a single dose 
of doxorubicin entrapped in positively charged liposomes. 
The thrombocytopenia appeared to be dose dependent, and was not 
affected by the method of doxorubicin administration. 
Anemia did not occur during these experiments. Although at the end of 
the 2 mg/kg experiment some drop in hemoglobin level is observed, related 
to a precedent inhibition of erythropoiesis as appears from the depression 
of reticulocyte count, the biological relevance is doubtful. On day 15 the 
serum albumin level in the 2 mg/kg free DXR treated group had decreased to 
6.7±0.6 g/1 (n-4), as expression of the DXR induced nephrotic syndrome. The 
concomitant disturbance in the water balance might be responsible for the 
observed lower hemoglobin level. However, the serum albumin level in lip" 
DXR 2 mg/kg treated group on day 15 is 25.0±3.2 g/1. (n-4), while Hb level 
does not differ from free DXR treated animals. The life span of the rat 
erythrocyte is estimated to be about 60 days (Schalm 1965). This means that 
in one day about 1.7% of erythrocytes are to be renewed. If the suppression 
of reticulocytes lasts about 7 days, as is observed in the 2 mg/kg 
experiment, the erythrocyte count and the hemoglobin level are expected to 
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decrease about 12%. This value is in agreement with the observations made. 
In the 1 and 2 mg/kg experiment reticulocyte counts are depressed in both 
lip"DXR and free DXR treated groups at least untili day 9. On day 11 the 
reticulocyte counts were in the range of control values. From day 13 till 
at least day 20 the reticulocyte counts in both treatment groups are about 
twice the control values, pointing at the activation of a compensatory 
mechanism. Overall toxicity at the 2 mg/kg dose level, administered on 
five consecutive days impedes longer observation. In the 1 mg/kg 
experiment, which allowed prolonged observation, no change in hemoglobin 
level occurs. The unchanged MCV values suggest that insertion of major 
parts of the liposomal membrane into the erythrocytes is less likely. 
The data on cellular DXR concentration in bone marrow cells are very 
remarkable. In the 1 mg/kg experiment the anthracycline related 
fluorescence declined after cessation of treatment as expected. In 
contrast, in the 2 mg/kg experiment, both in the free DXR, but less than in 
the lip'DXR treated rat the fluorescence steadily increased after the 
cessation of treatment. This phenomenon might indicate continuous 
doxorubicin levels in serum. The difference between the 1 mg/kg and 2 
mg/kg experiment might be explained by saturation phenomena in the 
mononuclear phagocytic system or a threshold for doxorubicin accumulation 
in bone marrow. The fluorescence levels in the lip" DXR exceeded those of 
free DXR. This observation cannot be explained by differences in 
differential counts ; no predominance of absolute numbers of phagocytic 
cells in bone marrow of free or liposome entrapped doxorubicin treated 
groups was found. 
Although anthracycline related fluorescence in the 2 mg/kg experiment 
increased untili days 8-10, bone marrow and subsequently peripheral blood 
show signs of recovery from this time on. Therefore, the meaning of 
intracellular anthracycline related fluorescence is not clear. The FCM 
does not discern metabolites, nor binding products of doxorubicin, in which 
fluorescent characteristics are preserved. However HPLC analysis on bone 
marrow cells did not show intracellular doxorubicin derived metabolites 
(data not shown). Further, this technique does not make any discrimination 
between the various maturation stages of bone marrow subpopulations or 
localisation of fluorescence at subcellular sites. For example, it might be 
possible that doxorubicin still bound to phospholipid constituents is 
phagocytosed in the lysosomal apparatus of differentiated myeloid cells, 
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which have lost their mitotic capacity. In this - highly speculative 
setting doxorubicin wouldn't do any harm. 
In conclusion, the administration of doxorubicin entrapped in 
negatively charged liposomes, which had shown to result in beneficial 
effects on doxorubicin induced cardiomyopathy and nephropathy with 
preservation of antitumor activity, in the IgM immunocytoma bearing male 
Lou/M Wsl rat has no advantage with regard to doxorubicin induced 
suppression of bone marrow activity at the dose levels investigated. 
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Chapter 9 
Concluding remarks and perspectives 
The entrapment of doxorubicin in negatively charged liposomes reduced 
cardiomyopathy and nephrotoxicity with preservation of its antitumor 
activity, whereas entrapment of doxorubicin in positively charged liposomes 
resulted in less antitumor activity than the free drug. Administration of 
doxorubicin in negatively charged liposomes did not result in an advantage 
with regard to bone marrow function. Entrapment of doxorubicin in 
negatively charged liposomes increases the therapeutic index by decreasing 
the toxic effects. 
From the present study it is not clear whether the severity of 
cardiomyopathy in the groups treated with liposome entrapped doxorubicin 
after prolonged observation times will yet reach the severity observed in 
the free doxorubicin treated group. This item is currently under 
investigation. 
The beneficiary effects are thought to be the result of prolonged 
doxorubicin levels, "infused" into plasma by liver and spleen, where 
doxorubicin encapsulating liposomes have been shown to be taken up 
preferentially. 
Selective uptake of liposomes by tumor cells is less likely because 
this would require the passage of liposomes across endothelial linings. In 
tumor tissue four types of capillaries have been discerned: 1) continuous 
capillaries, lined by an uninterrupted sheet of endothelial cells joined by 
typical tight junctions and resting on a well-formed basement membrane; 2) 
discontinuous capillaries with an incomplete endothelial lining lying on a 
continuous or fragmented basement membrane; 3) sinusoidal blood channels; 
sometimes the endothelial lining is lost and blood spaces are lined by 
tumor cells 4) giant capillaries, with a lumen that may exceed 50 um in 
diameter and consisting of a single layer of endothelial cells with little 
of no connective tissue (Poste 1984). The unpredictable variations in 
amounts of normal and abnormal vasculature in tumor tissue makes direct 
contact between liposomal entrapped cytostatic drug and tumor cells less 
likely. 
The preferential uptake of doxorubicin entrapped in liposomes in liver 
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and spleen has focused the attention to the mononuclear phagocytic system 
as a mediator in the cytostatic action of doxorubicin. The uptake of 
doxorubicin in macrophages has been shown to activitate them to 
cytotoxicity (Haskill, 1981, Martin 1982, Giavazzi 1984). Studies on this 
item performed by our cooperative groups have failed to show influx of 
macrophages or monocytes into the IgM immunocytoma as carriers for 
liposomal entrapped doxorubicin (Van Gessel, manuscript in preparation). 
Long-term liposome related toxicity has not been considered in this 
thesis. In current literature no elaborate studies on this topic are 
available. The (repeated) administration of liposomes in equivalent amounts 
to the administration of fat emulsions as used in total parenteral 
nutrition would not be scientifically justifiable. Although liposomes are 
made of biodegradable constituents, toxicity is not for that reason 
precluded. Furthermore, Poste (1984) warns against the possible 
consequences of blockading the mononuclear phagocytic system, not only by 
overwhelming the phagocytic capacity, but also by the inhibitory effects of 
cytostatic drugs on nucleic acid and protein synthesis in phagocytes. 
Repeated liposome administration in mice has been demonstrated to blockade 
the reticuloendothelial system, the degree of blockade being related to 
liposome size and composition, size and frequency of liposome dose and the 
presence of lipid peroxides (Allen, 1984). 
In order to explore the value of liposome entrapped cytostatic drugs 
for intraperitoneal administration and for targeting, a nude rat model 
inoculated intraperitoneally with an human ovarian cancer cell line is 
currently being developed at the Dutch National Institute of Public Health 
in collaboration with the Department of Cytology and Histology and the 
Department of Gynecology and Obstetrics (Catholic University Nijmegen). The 
efficacy of liposomes encapsulating doxorubicin, cisplatin, radiopharmaca, 
and/or monoclonal antibodies will be the objective of the investigations. 
The application of liposome entrapped drugs will first have to prove 
their advantages compared to conventional drug administration in clinical 
medicine. However, several problems have yet to be solved before 
application on a large scale becomes feasible; e.g. 
development of techniques for production of liposomes at large scale, 
reproducibility of liposome size using large scale production methods, 
sterility, not only outside the liposomes, but also inside the liposome, 
shelf life of liposome preparation, 
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stability of liposome suspensions (retention of entrapped drug, absence 
of aggregation and sedimentation), 
and additional toxicity studies. 
In case of studies in human beings, in addition to the standard 
requirements for the evaluation of toxicity of new drugs in cancer 
medicine, activation of the complement system and the development of an 
immune response should be surveyed. 
Most importantly, even if a well known drug is incorporated in 
liposomes, the whole should be considered as a new drug. 
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Summary 
Doxorubicin is a cytostatic drug with a wide spectrum of antitumor 
activity. Its use in clinical practice is associated with a dose dependent 
incidence of doxorubicin induced cardiomyopathy. The studies described in 
this thesis are intended to investigate whether the administration of 
doxorubicin entrapped in liposomes results in less cardiomyopathy and bone 
marrow toxicity with preservation of antitumor activity in the IgM 
immunocytoma bearing LOU/M Wsl rat. 
In chapter 1 an outline of the present investigation is given. 
In Chapter 2 theoretical considerations on increasing the therapeutic 
index are given. The attention is focused on liposomes as drug carriers, 
which are defined as microscopic structures consisting of one or more 
concentric lipid bilayers enclosing an equal number of aqueous spaces. The 
historical background is depicted. The several types of liposomes are 
described. Some chemical and physical properties of liposomes are reviewed, 
and the methods of preparation of liposomes are briefly explained. 
Subsequently, the interactions of liposomes with plasma proteins, with 
cells in vitro, and the fate of liposomes in vivo are discussed. The 
incorporation of drugs into liposomes is briefly mentioned. The 
experimental results of entrapment of methotrexate, cytosine arabinoside, 
and actinomycin-D are reviewed. Some other, still speculative, applications 
of liposome entrapped non-cytostatic drugs are referred to. 
In Chapter 3 the origin and chemistry of doxorubicin is discussed. 
The literature on analytical methods and pharmacokinetics is reviewed. The 
range of activity against human cancer Is depicted. The binding of 
doxorubicin to DNA, the doxorubicin generation of free radical formation, 
and its metal chelation properties, in addition to its membrane binding 
capacity are explained and their relevance for antitumor activity and 
toxicity is discussed. The doxorubicin induced toxicity, and cardiotoxicity 
in particular, are reviewed. The lines of investigations on diminishing 
doxorubicin induced cardiomyopathy, which have emerged in the literature in 
the past decade, are summarized. 
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In chapter 4 a method for analyzing doxorubicin and doxorubicinol in 
micro volumes of rat plasma is described. The extraction of doxorubicin, 
doxorubicinol, and daunorubicin is performed with chloroform-1-heptanol (1 
: 1) mixture. This organic solvent in a phase-volume ratio of 1 : 5 results 
in a 95% recovery of doxorubicin. Aglycone formation is prevented by using 
0.2 Μ HßPO^ in the aqueous phase. The analysis is performed on high-
performance liquid chromatographic equipment using the reversed-phase 
method. Daunorubicin is used as an internal standard. To circumvent the 
problems associated with the strong adsorptive effects of doxorubicin all 
glassware is silanized, and desipramine-HCl is added to the aqueous phase 
and the mobile phase. With this method the calibration curves for standard 
solutions of doxorubicin in water are linear over the concentration range 
from 0.1 iig/100 Ail to 10 ug/100 ul and for standard solutions of 
doxorubicin in plasma over the concentration range 1 ng/100 .pi plasma to 
100 iig/100 ліі plasma. Pharmacokinetic data, obtained with this method are 
given. 
Antitumor activity, cardiotoxicity, and nephrotoxicity induced by 
doxorubicin in male LOU/M Wsl inbred rats, each bearing a transplantable 
solid IgM immunocytoma are described in Chapter 5. Inoculation with 1 χ 10 
IgM immunocytoma cells subcutaneously in the left flank resulted on day 18 
after inoculation in tumors with a diameter of 15.8 ± 3.8 mm. Animals were 
treated with intravenous injections of doxorubicin (dose range 0.015 - 4.0 
mg/kg body weight on five consecutive days, followed by 1 weekly injection 
for 7 weeks. Tumor regression was observed with 0.5 mg doxorubicin/kg. 
Complete disappearance of the tumor was induced with 1 mg doxorubicin/kg. 
Light microscopic evidence of cardiotoxicity scored as grade III was only 
observed at a dose of 1.0 mg doxorubicin/kg. Histologic evidence of renal 
damage, which resulted in albuminuria and very low serum albumin levels, 
was seen above a dose of 0.5 mg doxorubicin/kg. In the group that received 
1.0 mg doxorubicin/kg the serum albumin level decreased from 33.6 ± 4.1 to 
1.5 ± 0.5 g/liter. Ascites and hydrothorax were observed simultaneously. 
The same experiments have been performed with non-tumor-bearing rats, in 
which no major differences have been observed. In conclusion, doxorubicin 
induced antitumor activity, cardiotoxicity and nephrotoxicity can be 
studied simultaneously in the same LOU/M Wsl rat. Albuminuria due to renal 
damage led to extremely low serum albumin levels. Ascites and hydrothorax 
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are not necessarily a consequence of the observed cardiomyopathy. 
Because severe doxorubicin induced nephropathy has been observed in 
the study described in the previous chapter, in Chapter 6 the question is 
raised whether nephropathy adds to, or even might be responsible for 
doxorubicin induced cardiomyopathy in rats. The temporal relationship 
between the onset of doxorubicin induced cardiomyopathy and nephropathy in 
male and female LOU/M Wsl rats has been studied. Modification of the 
treatment schedule did not circumvent nephrotoxicity. The 1 mg 
doxorubicin/kg dose, administered i.v. on five consecutive days and 
thereafter weekly reaching a cumulative dose of 13 mg doxorubicin/kg 
resulted in male LOU/M Wsl rats in albuminuria of more than 10 g/liter at 
day 14, whereas female rats only reached a similar level of albuminuria > 
10 g/liter at day 49. As a consequence serum albumin levels in male LOU/M 
Wsl rats decreased to levels below 10 g/liter, while female rats maintained 
serum albumin levels till day 49. At day 10 in male and female rats a grade 
1.0 - 1.5 cardiomyopathy score, assessed according to the modified 
Billingham scoring system, was found gradually increasing to grade 2.5 -
3.0 cardiomyopathy, both in males and females, on day 49. In male rats the 
nephropathy developed steadily from day 14 and thereafter, whereas in 
females the rate of development of kidney damage was slower and at the 
endpoint of the study the severity of kidney lesions was less in comparison 
to male rats. The onset of cardiomyopathy and nephropathy was 
simultaneously. In conclusion, the doxorubicin induced cardiomyopathy 
observed in LOU/M Wsl rats is a phenomenon which is independent of the 
nephropathy. This is in agreement with experience in clinical practice, 
where doxorubicin induced nephropathy is not observed in contrast to 
cardiomyopathy. Because both phenomena are independent, the nephrotic 
syndrome does not depreciate the value of the rat as a model for studies on 
doxorubicin induced cardiomyopathy. 
In Chapter 7 the effects of entrapment of doxorubicin in liposomes on 
reduction of cardiotoxicity and nephrotoxicity with preservation of 
antitumor activity are described. Doxorubicin has been encapsulated in 
negatively charged liposomes (lip" DXR) composed of egg 
phosphatidylcholine, cholesterol and phosphatidylserine and in positively 
charged liposomes (lip DXR) composed of phosphatidylcholine, cholesterol 
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and stearylamine. Doxorubicin, lip" DXR, and lip DXR have been adminstered 
i.v. (0, 0.25, 0.5, 1.0 and 2.0 mg/kg) on day 17 for 5 consecutive days and 
then weekly into IgM immunocytoma bearing male LOU/M Wsl rats. Control 
animals died of progressive tumor growth 27 days after inoculation. 
Antitumor activity was dose dependent for all three preparations. Free DXR 
and lip" DXR showed the same antitumor activity. Lip DXR had less 
antitumor activity. The overall survival of tumor-bearing animals treated 
with 2.0 mg/kg lip" DXR was significantly prolonged (p < 0.05) in 
comparison to the animals treated with 2.0 mg/kg free DXR. Treatment with 
free DXR resulted after 47 days in grade III cardiomyopathy, whereas 
treatment with lip" DXR resulted in grade I cardiomyopathy. Compared to 
treatment with free DXR, treatment with DXR encapsulated in either type of 
liposome resulted in less kidney damage, less albuminuria and preservation 
of serum albumin levels. Treatment with liposomal entrapped doxorubicin 
resulted in lower tissue doxorubicin levels at 4 h and 24 h after one i.v. 
injection of 1 mg doxorubicin/kg when compared to free drug. Lip" DXR, 
however, resulted in high doxorubicin tissue levels in spleen and liver. It 
is concluded that treatment with lip" DXR or lip DXR resulted in prolonged 
survival, less albuminuria, higher serum albumin levels, less lesions In 
heart and kidney, correlating with lower DXR levels in these organs. Only 
lip" DXR had the same antitumor effect as free DXR, resulting in a 
therapeutical advantage due to less toxicity. 
Because bone marrow toxicity is the dose limiting toxicity in clinical 
practice, in Chapter 8 hematological parameters during and after treatment 
with lip" DXR, which had been shown to result in less toxicity in the 
studies described in the previous chapter, were compared to treatment with 
free DXR. It was concluded that administration of lip" DXR at the dose 
levels investigated did not result in an advantage with regard to extent 
and duration of suppresion of bone marrow activity. Bone marrow recovery 
set in despite increasing cellular doxorubicin levels; these latter were 
measured using laser flow cytometric techniques. 
In Chapter 9 some questions about the applicability of liposomes as 
drug carriers in clinical medicine and lines for future research are 
discussed. 
158 
SAMENVATTING EN CONCLUSIES 
Doxorubicine is een stof die de celdeling remt (cytostaticum) met een 
breed werkingsspectrum. Het wordt daarom bij de behandeling van 
gezwelsziekten veelvuldig gebruikt. De toepassing ervan gaat gepaard met 
een met de totale dosis toenemende kans op beschadiging van de hartspier. 
Het onderzoek, dat in dit proefschrift beschreven wordt, heeft als 
belangrijkste doelstelling na te gaan of de toediening van doxorubicine 
ingebouwd in liposomen resulteert in minder beschadiging van de hartspier 
en remming van de activiteit van het beenmerg met behoud van antitumor 
werking. Voor dit doel werd de LOU/M Wsl rat, geënt met een IgM 
immunocytoma als model bruikt. 
In hoofdstuk 1 wordt de opbouw van het onderzoek, dat ten grondslag 
ligt aan dit proefschrift, geschetst. 
In hoofdstuk 2 wordt een theoretische beschouwing over het begrip 
therapeutische index gegeven. Vervolgens wordt de aandacht gericht op 
liposomen als dragers van geneesmiddelen. Liposomen zijn microscopische 
structuren, die uit een of meer concentrische bimoleculaire laagjes vet 
bestaan. Deze omsluiten een aantal ruimten gevuld met water, dat gelijk is 
aan het aantal membranen waaruit het liposoom bestaat. De historische 
achtergrond wordt geschetst. Een beschrijving van de verschillende typen 
liposomen wordt gegeven. Enige chemische en fysische eigenschappen van 
liposomen worden kort samengevat. De bereidingswijzen van liposomen worden 
beknopt uitgelegd. Vervolgens wordt de wisselwerking van liposomen met 
plasma-eiwitten en met cellen in de reageerbuis en het lot van liposomen in 
levende dieren besproken. Het concept om geneesmiddelen in te bouwen in 
liposomen wordt belicht. De experimentele ervaringen met cytostatica als 
methotrexaat, cytosine arabinoside en actinomycine - D worden gemeld. Er 
wordt verwezen naar speculatieve toepassingen van andere dan cytostatische 
geneesmiddelen ingebouwd in liposomen. 
In hoofdstuk 3 wordt de herkomst en de chemische achtergrond van 
doxorubicine besproken. Gebaseerd op de literatuur wordt een overzicht van 
analytische methoden en farmakokinetiek gegeven. Het werkingsspectrum in de 
humane oncologie wordt geschilderd. Er wordt ingegaan op de binding van 
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doxorubiclne aan DNA, op de door doxorubicine uitgelokte opwekking van 
vrije radicalen, op de eigenschap metalen te cheleren en op het vermogen 
zich aan membranen te binden en de betekenis hiervan voor antitumorwerking 
en toxiciteit. De door doxorubicine geïnduceerde toxiciteit en de 
beschadiging van de hartspier in het bijzonder, worden besproken. De lijnen 
van onderzoek naar mogelijkheden om de beschadigende werking op de 
hartspier te verminderen worden samengevat. 
In hoofdstuk 4 wordt een methode voor de meting van doxorubicine en 
doxorubicinol in microvolumes ratteplasma beschreven. De onttrekking van 
doxorubicine, doxorubicinol en daunorubicine wordt uitgevoerd met mengsel 
van chloroform-1-heptanol (1:1). Hiermee wordt in een verhouding 
onttrekkingsvloeistof : plasma - 5 : 1 , 95% van de doxorubicine aan een 
monster onttrokken. De vorming van aglyconen wordt voorkomen door 0.2 M 
HTPOA in de waterfase te gebruiken. De analyse wordt uitgevoerd op een hoge 
druk vloeistof chromatograaf, gebruik makend van de "reversed phase" 
methode. Als interne standaard wordt daunorubicine gebruikt. Om adsorptie 
van doxorubicine te vermijden wordt het laboratorium-hulpmateriaal 
voorbewerkt met 2% trimethylchlorosilaan in tolueen en wordt desipramine-
HC1 aan de waterfase en het loopmiddel toegevoegd. De toepassing van 
voornoemde methode resulteert in Ijklijnen voor oplossingen doxorubicine in 
water, die lineair zijn in het traject van 1 ng/ml tot 100 •pg/ml. Voor 
doxorubicine in plasma over een traject van 10 ng/ml tot 1 mg/ml. De 
resultaten van onderzoek naar farmakokinetische parameters, verkregen met 
deze methode 
De antitumor werking, de beschadiging van hartspier en nier 
teweeggebracht door doxorubicine in mannelijke LOU/M Wsl ratten, geint met 
een als een solide tumor op te vatten IgM immunocytoom, worden beschreven 
in hoofdstuk 5. Enting met 1 χ 10 IgM immunocytoma cellen onderhuids op de 
linkerflank leidt op dag 18 na inoculatie tot een tumor met een diameter 
van 15.8 ±.3.8 mm. Aan de dieren wordt vervolgens doxorubicine intraveneus 
toegediend (dosering opklimmend van 0.015-4.0 mg/kg lichaamsgewicht) op 5 
achtereenvolgende dagen, gevolgd door een toediening per week gedurende 7 
weken. Afneming van tumor wordt gezien bij een dosis van 0.5 mg/kg. 
Verdwijning van tumor wordt waargenomen bij een dosis van 1 mg/kg. Met de 
lichtmicroscoop wordt graad III beschadiging van de hartspier vastgesteld 
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bij ratten behandeld met 1 mg/kg lichaamsgewicht. Histologische tekenen 
van nierbeschadiging, leidend tot albuminurie en zeer lage serum 
albuminespiegels worden waargenomen boven een dosis van 0.5 mg/kg. In de 
groep ratten, behandeld met 1.0 mg/kg nam de serum albumine concentratie af 
van 33.6 ± 4.1 g/1 tot 1.5 ± 0.5 g/1. Ascites en hydrothorax treden 
gelijktijdig op. In niet-tumordragende dieren worden dezelfde resultaten 
verkregen. Geconcludeerd wordt dat cytostatische aktiviteit en beschadiging 
van hartspier en nier gelijktijdig in de LOU/M Wsl rat kunnen worden 
bestudeerd. Voorts wordt vastgesteld dat de ascites en hydrothorax meer 
waarschijnlijk het gevolg zijn van de zeer lage serum albumine 
concentraties dan van het falen van hartspierwerking. 
In hoofdstuk 6 wordt ingegaan op de vraag of de nierbeschadiging 
bijdraagt of zelfs verantwoordelijk is voor de beschadiging van de 
hartspier bij ratten. Het ontstaan van door doxorubicine veroorzaakte 
beschadiging van hartspierbeschadiging en nierbeschadiging wordt in de tijd 
bestudeerd. Het onderzoek wordt zowel bij mannelijke als vrouwelijke 
ratten uitgevoerd, omdat in voorbereidende studies gebleken was dat er een 
geslachtsgebonden verschil in gevoeligheid voor door doxorubicine 
veroorzaakte toxiciteit is. In overeenstemming met de ervaringen in de 
kliniek, waar door doxorubicine veroorzaakte nierbeschadiging niet wordt 
waargenomen, levert dit onderzoek geen aanknopingspunt voor een oorzakelijk 
verband tussen nierbeschadiging en hartspierbeschadiging, omdat de 
nierbeschadiging en hartspierbeschadiging gelijktijdig tot ontwikkeling 
komen en vooral omdat de nierbeschadiging bij mannelijke ratten ernstiger 
is dan bij vrouwelijke dieren, terwijl de beschadiging van de hartspier 
voor beide geslachten zich gelijkelijk ontwikkelt. 
In hoofdstuk 7 worden de resultaten van behandeling met doxorubicine 
ingebouwd in negatief geladen liposomen samengesteld uit ei-
phosphatidylcholine, cholesterol en phosphatidyl serine en van doxorubicine 
ingebouwd in positief geladen liposomen samengesteld uit 
phosphatidylcholine, cholesterol en stearylamine beschreven. Onderzocht in 
de mannelijke LOU/M Wsl rat, geënt met het IgM immunocytoom blijkt 
doxorubicine in negatief geladen liposomen een antitumor werking te hebben 
die niet verschilt van vrij doxorubicine, terwijl de antitumor activiteit 
van doxorubicine in positief geladen liposomen hierbij ten achter blijft. 
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Op dag 47 van de behandeling leidt behandeling met vrij doxorubicine (1 
mg/kg) tot graad III beschadiging van de hartspier, terwijl behandeling met 
doxorubicine (1 mg/kg) ingebouwd in negatief geladen liposomen de 
hartspierbeschadiging beperkt tot graad I. Wat betreft nierbeschadiging, 
albuminurie en serum albuminespiegel bieden beide typen liposomen 
vergelijkbare voordelen. Metingen van doxorubicine concentraties in plasma 
en weefsels tonen 4 en 24 uur na een eenmalige intraveneuze injectie van 
doxorubicine ingebouwd in liposomen lagere gehaltes in weefsels aan, met 
name in hart en nier. Toediening van doxorubicine in negatief geladen 
liposomen echter geeft in lever en milt hoge gehaltes. Omdat doxorubicine 
ingebouwd in negatief geladen liposomen resulteert in minder bijwerkingen 
en gelijkblijvende antitumor werking, vergeleken met behandeling met vrij 
doxorubicine, kan men besluiten dat behandeling met doxorubicine ingebouwd 
in voornoemde liposomen tot een therapeutisch voordeel leidt. 
In hoofdstuk 8 wordt het effekt van toediening van doxorubicine 
ingebouwd in negatief geladen liposomen op hematologische parameters 
vergeleken met het effekt van vrij doxorubicine. Bij de onderzochte 
doseringen en toedieningsschema, heeft de eerstgenoemde toedieningsvorm 
geen kortere of minder ernstige beenmergremming tot gevolg. Het herstel van 
de aktiviteit van het beenmerg treedt in, hoewel cellulaire doxorubicine 
concentraties, gemeten met de laser flowcytometer, in beenmergcellen 
toenemen. 
In hoofdstuk 9 worden de problemen, die nog opgelost moeten worden, 
alvorens liposomen als dragers van geneesmiddelen, op grotere schaal op hun 
waarde voor klinische toepassing kunnen worden getoetst, besproken. Voorts 
worden nieuwe lijnen van onderzoek besproken. 
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heeft aangebracht. Wim de Jong dank ik voor het kritisch volgen van de 
experimenten en het doorlezen van het manuscript. 
De Afdeling Fotografie van het RIVM ben ik erkentelijk voor de lijn­
en halftoonfoto's, die het proefschrift illustreren. 
Dankzij de medewerking van vele collegae heb ik het werk in het 
laboratorium met de klinische werkzaamheden kunnen combineren. 
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Curriculum vitae 
De schrijver van dit proefschrift werd geboren op 2 mei 1950 te 's-
Hertogenbosch. Na de lagere school volgde hij de gymnasium В opleiding aan 
het St.Janslyceum aldaar. Het eindexamen werd in 1968 afgelegd. In 
hetzelfde jaar begon hij de studie Geneeskunde aan de Rijksuniversiteit te 
Utrecht. Het artsexamen werd op 31 januari 1975 afgelegd. De militaire 
dienstplicht vervulde hij als reserve Ie luitenantarts bij de Geneeskundige 
Compagnie van de 13e Brigade te Oirschot. Op 1 mei 1976 begon hij de 
opleiding tot internist aan de afdeling Inwendige Geneeskunde (Opleider: 
Dr.J.A.Flendrig) van het Catharina Ziekenhuis te Eindhoven. Vanaf 1 juli 
1978 werd de opleiding voortgezet aan de Afdeling Inwendige Geneeskunde van 
het Academisch Ziekenhuis te Utrecht (Hoofden: Prof.Dr.A. Struyvenberg en 
Prof.Dr.J. van der Sluys Veer). Hij werd als internist ingeschreven in het 
Specialistenregister op 1 mei 1981. Vanaf die datum was hij als Fellow van 
het Koningin Wilhelmina Fonds verbonden aan het Antoni van Leeuwenhoekhuis 
te Amsterdam. Sedert 1 mei 1983 is hij werkzaam als wetenschappelijk 
ambtenaar bij de Afdeling Medische Oncologie (Hoofd: 
Prof.Dr.D.J.Th.Wagener) van de Kliniek voor Inwendige Geneeskunde (Hoofd: 
Prof.Dr.A. van 't Laar) van het St.Radboud Ziekenhuis te Nijmegen. Hij is 
als consulent Medische Oncologie verbonden aan het Integraal Kankercentrum 
Oost en als zodanig werkzaam voor het Integraal Kankercentrum Zuid. 
Hij is gehuwd met Louise J.M. Suyskens. Zij hebben twee kinderen. 
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STELLINGEN 
behorende bij het proefschrift van 
0 G С M van Hoesel 
I 
De met een IgM immunocytoom gelnoculeerde Lou M/Wsl rat maakt gelijktijdige 
bestudering van antitumor werking en toxiciteit van cytostatica mogelijk. 
Dit proefschrift. 
II 
Anthracyclines brengen in een aantal species nephropathie, albuminurie en 
hypoalbuminaemie teweeg. Daarom zijn ascites en hydrothorax in het 
proefdiermodel niet noodzakelijkerwijs uiting van cardiomyopathie. 
Dit proefschrift. 
III 
Behandeling van een IgM immunocytoomdragende Lou M/Wsl rat met doxorubicine 
ingebouwd in negatief geladen liposomen resulteert in antitumoractiviteit, 
die vergelijkbaar is met conventionele behandeling met doxorubicine, maar 
heeft minder beschadiging van de hartspier en nier ten gevolge. 
Dit proefschrift. 
IV 
De toediening van doxorubicine ingebouwd in liposomen resulteert in een 
wezenlijk andere verdeling van doxorubicine in weefsels, vergeleken met de 
conventionele toediening van doxorubicine. 
Dit proefschrift. 
De duur en de ernst van de remming van de activiteit van het beenmerg in de 
Lou M/Wsl rat wordt door toediening van doxorubicine ingebouwd in negatief 
geladen liposomen niet voordelig beïnvloed in vergelijking met de 
conventionele toediening van doxorubicine. 
Dit proefschrift. 
VI 
De toxiciteit en het uitblijven van verlenging van de overlevingsduur zijn 
argumenten tegen de aanbeveling van de Gastrointestinal Tumor Study Group 
om patiënten met een rectumcarcinoom, dat door de wand van het rectum is 
gegroeid en/of aanleiding heeft gegeven tot lymfkliermetastasen, behalve 
met uitwendige bestraling, ook met 5-fluorouracil en semustine te 
behandelen. 
GITSG N Engl J Med 1985; 312: 1465 
Editorial N Engl J Med 1985; 312: 1512 
VII 
Een instrument om de uitwerking van de consultverlening in het kader van de 
integrale kankercentra op de kwaliteit van de patiëntenzorg te meten 
ontbreekt. Feitelijk is een prospectief vergelijkend onderzoek niet 
mogelijk. 
VIII 
Na chemotherapie levert toevoeging van bestraling van de primaire 
lokalisatie van een kleincellig anaplastisch bronchuscarcinoom geen 
wezenlijke bijdrage aan het resultaat van de behandeling. 
Souhami et al. Br Med J 1984; 288: 1643 
IX 
Het meten van thyreoglobulinespiegels na verwijdering van de schildklier 
waarin zich een gedifferentieerd schildkliercarcinoom bevindt, levert een 
bijdrage aan de vaststelling van residu tumor of metastasen en behoeft niet 
in hypothyreote toestand plaats te vinden. 
J.H.Bolk et al. Neth J Med 1985; 28: 340 
X 
Het aantal varianten van de klassificatie van colon- en rectumcarcinomen 
volgens Dukes is zodanig groot dat toepassing van de hierop gebaseerde 
klassificatie vaker leidt tot misverstand dan tot een ondubbelzinnige 
samenvatting van de anatomische uitbreiding van de tumor. De TNM 
klassificatie verdient de voorkeur. 
XI 
Het peil waarop in Nederland in centra patiënten met testiscarcinoom 
behandeld worden, biedt voldoende infrastructuur om een klinisch onderzoek 
naar de waarde van het zogenaamde "wait and see" beleid bij klinisch 
stadium I testiscarcinoom te rechtvaardigen, mits het accent meer op "see" 
dan op "wait" ligt. 
XII 
De bovenbuik bevindt zich boven de onderbuik en maakt in gelijke mate deel 
uit van de linker en van de rechter buik. 
Q.G.C.M, van Hoesel Nijmegen 8 november 1985 



